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Abstract 142 
The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation 143 
of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis 144 
and management of aspergillosis. Of the numerous recommendations a few are summarized here. 145 
Chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients 146 
with suspicion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct 147 
microscopy preferably using optical brighteners, histopathology and culture are strongly 148 
recommended. Serum and BAL galactomannan is recommended as markers for the diagnosis of IA. 149 
PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species 150 
complex level is strongly recommended for all clinically relevant Aspergillus isolates; antifungal 151 
susceptibility testing should be done in patients with invasive disease in regions with resistance found 152 
in contemporary surveillance programmes. Isavuconazole and voriconazole are the preferred agents 153 
for first line treatment of pulmonary IA, while liposomal amphotericin B is moderately supported. 154 
Combinations of antifungals as primary treatment options are not recommended. TDM is strongly 155 
recommended for patients receiving posaconazole suspension or any form of voriconazole for IA 156 
treatment, and in refractory disease, where a personalized approach considering reversal of 157 
predisposing factors, switching drug class and surgical intervention is also strongly recommended. 158 
Primary prophylaxis with posaconazole is strongly recommended in patients with acute myelogenous 159 
leukaemia or myelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is 160 
strongly recommended in high-risk patients. We strongly recommend treatment duration based on 161 
clinical improvement, degree of immunosuppression and response on imaging. 162 
  163 
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Introduction 164 
This is the third fungal diagnosis and management clinical guideline published in cooperation with 165 
various European scientific societies [1-9]. This part of the guideline regarding invasive and chronic 166 
aspergillosis is a condensation of all the recommendations made by the guideline subcommittees and 167 
presented in tables for easier and faster reading. More details on how the recommendations were 168 
arrived at are planned in supplementary publications. This Aspergillus guideline will follow the style of 169 
other guidelines by including diagnostic and therapeutic guidance. Other scientific groups have 170 
published guidelines on this topic previously and all follow the common goal to provide clinicians with 171 
best guidance in their everyday working environment. Our goal was to provide a comprehensive 172 
European guideline focusing on the life-threatening diseases caused by Aspergillus spp. 173 
 174 
Methods 175 
Author panel recruitment and organisation was similar to what was done previously [10]. In brief, 176 
experts in the field were nominated by the three societies ESCMID, ECMM, and ERS. The total 53 177 
authors were grouped into their special fields of expertise. Subgroup coordinators were responsible 178 
for the first draft of recommendations. There were two face-to-face meetings followed by numerous 179 
electronic exchanges. Some of the first recommendations were presented at ECCMID 2014. This 180 
summary was reviewed and approved by all authors and sent to the ESCMID guideline director for 181 
public review. Then the final version was submitted to Clinical Microbiology and Infection for 182 
additional peer review and subsequent publication. Only the rationale of the chronic pulmonary 183 
aspergillosis (CPA) guideline was published ahead of time [11]. 184 
Questions were predefined and modified where appropriate and the strength of recommendation and 185 
quality of evidence was slightly modified (Table 1) [12]. Diagnostic tests are regarded as interventions. 186 
 187 
Summary of Recommendations 188 
Diagnostic Procedures 189 
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Early diagnosis of invasive aspergillosis (IA) is a challenge and should be based on the integration of 190 
clinical, radiological and microbiological data. 191 
 192 
Thoracic Imaging 193 
In patients at risk for IA with fever of unknown origin or clinical symptoms of lower respiratory tract 194 
infection who remain febrile despite broad-spectrum antibacterial treatment, thin-section chest 195 
computed tomography (multidetector (MDCT), multislice (MSCT), spiral CT, high resolution CT) at 196 
optimized dose (according to ALARA ͞As Low As Reasonably Achievable͟ principle) is the imaging 197 
modality of choice (AII) [13-23]. Pulmonary CT angiography may be of interest in the early diagnosis of 198 
IA by depicting directly vessel occlusion at the level of a suspicious fungal lesion with a potential high 199 
negative predictive value regarding imaging evaluation [24-26], and is required in case of haemoptysis 200 
(AII). In selected patients where CT is not wanted or feasible, MRI of the lungs may represent an 201 
alternative imaging to thin-section MSCT [27-32], PET-CT being of modest interest in the diagnostics 202 
of IA [33, 34]. 203 
No CT scanning technique is 100% sensitive or specific for pulmonary IA [35-37]: Classical CT findings 204 
of angioinvasive aspergillosis include macronodule(s) >1 cm, which may be surrounded by a halo of 205 
ground-glass attenuation (halo sign, early phase, inconstant) [36, 38-40], pleural based wedge-shaped 206 
areas of consolidation [41], alveolar consolidations [36, 42, 43], masses (especially in SOT recipients) 207 
[15, 38], internal low attenuation[44], reverse halo sign [45], cavity or air-crescent sign (delayed 208 
finding), ground glass opacities and pleural effusion [17, 35, 46]. Bronchoinvasive forms may appear 209 
as tracheal or bronchial wall thickening, centrilobular nodules with tree in bud appearance [14] in a 210 
patchy distribution, predominant peribronchial areas of consolidation [47] or bronchopneumonia [46] 211 
(Table 2). 212 
 213 
Bronchoalveolar Lavage and Biopsies 214 
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Other diagnostic procedures include early bronchoalveolar lavage (BAL) (AII) [48-54], guided by CT-215 
findings [55, 56], and less frequently CT-guided transthoracic biopsies, video-assisted thoracoscopic 216 
surgery (VATS), open lung biopsies, transbronchial biopsies or convex endobronchial ultrasound 217 
transbronchial needle aspiration (EBUS-TBNA), the latter technique appearing to be a promising 218 
procedure in this setting [28, 57-72]. Contraindications to these techniques need to be considered. 219 
 220 
Imaging of other Sites 221 
Moreover, according to clinical symptoms, paranasal CT, CT or MRI of the CNS as well as abdominal CT 222 
may also be required. In particular, findings of sinusitis with bone erosion may be observed, 223 
intracranial and/or intraorbital extension of the disease being best evaluated by MRI [73-75]. In the 224 
brain, due to direct spread from paranasal sinuses or haematogenous dissemination, meningeal 225 
enhancement or empyema, cerebral abscess, mycotic aneurysms as well as haemorrhagic lesions and 226 
rarely stroke may be seen [76-79]. 227 
 228 
Microscopy and Culture 229 
Both microscopy and culture should be attempted on appropriate specimens from patients at risk for 230 
IA (AII) with a priority for culture in most cases where insufficient material is available. Demonstrating 231 
tissue invasion by hyphae through microscopic examination of biopsy or autopsy material provides a 232 
diagnosis of proven invasive fungal infection. However, the sensitivity of microscopy for IA is 50% at 233 
best [80]. Specimens may be examined as a wet mount preparation with or without the addition of 234 
10% potassium hydroxide. Fluorescent dyes such as Calcofluor White™ or Blancophor™ have the 235 
advantages of increased sensitivity, rapid turnaround time, and broad applicability but are not specific 236 
for Aspergillus (AII). Gomori's methenamine silver stain (GMS) and periodic acid-Schiff (PAS) can be 237 
applied to histological sections and smears and should be conducted in all cases in which IA is 238 
considered a possibility (Table 3). Respiratory secretions from patients with suspected aspergillosis 239 
must be processed rapidly for culture to prevent overgrowth by bacteria and yeasts. To achieve 240 
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optimal recovery of Aspergillus from BAL fluid, centrifugation of the sample is advised with 241 
investigation of the sediment (AIII). It is recommended that cultures of high volume untreated sputum 242 
and BAL should be performed as opposed to culturing small volumes of digested, liquefied samples 243 
[81] (Table 4). Specific media to support fungal growth are recommended. Species identification to the 244 
complex level should be done for clinically relevant isolates from patients who need antifungal 245 
treatment, and for epidemiological purposes (AIII) (Table 5). 246 
 247 
Non-Culture Based Assays 248 
Galactomannan (GM) detection in fluids (especially BAL) is more sensitive than culture for diagnosis of 249 
IA. GM is reported as optical density index (ODI). In serum samples an ODI cut-off of 0.5 results in high 250 
sensitivity in haematological patients in the absence of mould-active prophylaxis (AI) (Table 6). Serial 251 
screening for serum GM in prolonged neutropenia and in allogeneic stem cell transplantation 252 
recipients during the early engraftment phase has a high sensitivity and negative predictive value (NPV) 253 
for IA (AII) [82]. Serial screening is not recommended in patients on mould-active prophylaxis [83]. 254 
Sensitivity of serum GM testing is significantly lower in non-neutropenic versus neutropenic patients 255 
[84]. Decrease of the ODI during the first two weeks of antifungal therapy is a reliable predictor of a 256 
satisfactory response in cancer patients [85]. GM detection in BAL specimens has an excellent 257 
performance with evidence that ODI of 0.5–1.0 has decreased predictive values compared with results 258 
of >1.0 [86] (AII) (Table 7). The test also has diagnostic value in patients undergoing lung 259 
transplantation or who are in intensive care [87-89]; a sensitivity of 100% and a specificity of 90.4% 260 
was defined at cut-off of 1.5 [87]. 261 
(1-3)-β-D-glucan (BDG) is a constituent of the cell wall of many species and genera of fungi and is 262 
released into body fluids in association with fungal infection. A limited role is given for the exclusive 263 
testing of the BDG in diagnosing IA (BII) (Table 8), however, the combination with GM or PCR improves 264 
specific detection [90]. 265 
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The Aspergillus lateral flow LFD assay can be performed on serum and on BAL samples, but at the time 266 
of writing this assay is not commercially available [91] (Table 9). 267 
Aspergillus PCR has been applied mostly to blood and BAL fluid. For both sample types, a combination 268 
with other biomarkers increases the likelihood of IA [92, 93]. The performance of serum PCR is not 269 
significantly different from that of whole blood [94-97]. Prospective screening of high-risk 270 
haematological patients by a combination of GM and PCR improves the diagnostic accuracy and is 271 
associated with an earlier diagnosis [98, 99] (Table 10 and 11). 272 
On hyphal positive biopsy samples molecular detection of fungi is strongly recommended (AII). If no 273 
hyphae are visible the diagnostic yield of molecular methods is lower (Table 12). Recommendations 274 
for storage of original samples and isolates are given in table 13. Antibody detection tests are not 275 
supported for the diagnosis of IA (CII) (Table 14). 276 
 277 
Antifungal Susceptibility Testing 278 
Resistance to antifungal agents is an increasing problem in Aspergillus diseases [100-102]. Aspergillus 279 
species can be intrinsically resistant to polyenes and azoles [103], or may acquire resistance following 280 
exposure to azole compounds [104]. Acquired resistance to azoles is mainly found in Aspergillus 281 
fumigatus and is reported globally [100, 101, 105-108]. Resistance may also develop through exposure 282 
to azole fungicides in the environment [109-112]. As resistant spores are present in ambient air, 283 
patients may present with azole-resistant Aspergillus disease without previous azole therapy [113, 284 
114]. Individual Aspergillus colonies from a single specimen may harbour different resistance profiles 285 
[117], hence multiple colony testing (up to 5 colonies) is recommended to increase sensitivity for azole-286 
resistance detection (BIII). 287 
In clinical laboratories, species identification to complex level is recommended for all clinically 288 
significant isolates (BIII). Some species are intrinsically resistant to either azoles or amphotericin B 289 
(AmB) (Tables 5, 15, 16 and 17). 290 
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Antifungal susceptibility testing of Aspergillus isolates should be performed in patients with invasive 291 
disease with the exception of azole naïve patients in regions with no resistance found in contemporary 292 
surveillance programmes aŶd regularlǇ for epideŵiologiĐal purposes iŶĐludiŶg шϭϬϬ isolates. This is 293 
particularly important in patients who are unresponsive to antifungal treatment, or in patients who 294 
are clinically suspected having an azole-resistant pathogen (AIII) (Table 15). If MIC-testing is not 295 
available, routine agar screening can be used to detect azole resistance (Table 16) [118]. However, 296 
such isolate should be referred to a mycology reference laboratory for MIC testing. Clinical breakpoints 297 
for interpretation of azole and AmB MICs against Aspergillus are currently available for European 298 
Committee on Antimicrobial Susceptibility Testing (EUCAST) microdilution method but remain 299 
undetermined for Clinical & Laboratory Standards Institute (CLSI) methodology. Accordingly, EUCAST 300 
(AII) or CLSI broth microdilution methods (BII) can be used for determination of routine MICs for 301 
clinical guidance and for epidemiological resistance surveillance (AII). Both itraconazole and 302 
voriconazole (AII) should be tested to ensure detection of the voriconazole-resistance mutation 303 
TR46/Y121F/T289A [118]. Posaconazole resistance without itraconazole resistance has not been 304 
reported (Table 17). EUCAST (BIII) or CLSI broth microdilution methods (CIII) can be used to determine 305 
AmB MICs but although a correlation between MIC and clinical outcome exist for A. terreus and A. 306 
flavus  it remains to be documented for A. fumigatus due to the scarcity of resistant isolates (Table 307 
17). 308 
Voriconazole and isavuconazole are recommended for the treatment of IA due to species showing high 309 
AmB MICs (Table 19). Liposomal AmB (L-AmB) or AmB lipid complex (ABLC) are recommended for 310 
species with intrinsic high azole MICs (Table 18 and 20). In aspergillosis due to A. fumigatus specifically, 311 
voriconazole or isavuconazole are recommended if the isolate is voriconazole susceptible (EUCAST MIC 312 
чϭ mg/l) (AI). If resistant (voriconazole MIC >2 mg/l), L-AmB therapy is recommended (AIIu). It is 313 
unknown if patients infected with A. fumigatus with voriconazole MIC 2 mg/l (intermediate), respond 314 
less well to voriconazole monotherapy. These patients may have an increased probability of failing 315 
voriconazole monotherapy, and combination therapy with an echinocandin or L-AmB monotherapy 316 
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should be considered for invasive disease (AIII) (Table 20). In azole-resistant CPA, L-AmB or micafungin 317 
can be considered (BII) if surgical intervention is precluded [11]. In settings with environmental azole 318 
resistance, no change to the primary regimen for IA is recommended when resistance rates are <10% 319 
(AIII). If azole resistance rates are >10%, first line therapy with voriconazole plus echinocandin (BIII) or 320 
L-AmB (BIII) is recommended. 321 
 322 
Therapeutic Drug Monitoring (TDM) 323 
Patients with IA often have multiple conditions associated with their underlying disease and its 324 
treatment that affects the absorption, distribution, metabolism, and clearance of antifungal 325 
medications [119]. As a result, standardized dosing recommendations for antifungals used in the 326 
prevention or treatment of IA may not achieve effective or safe drug exposures in all patients. 327 
Moreover, a subset of patients with severe infections or difficult to treat sites (e.g. CNS) or infections 328 
caused by Aspergillus spp. with elevated MICs may require higher drug exposures. Therapeutic drug 329 
monitoring (TDM) is often the most direct laboratory approach for identifying patients at jeopardy for 330 
treatment failure or toxicity because of inadequate or excessive drug exposures, and can be used to 331 
fine-tune antifungal dosing to improve the probability of optimal outcomes (Table 21). 332 
 333 
Itraconazole 334 
For itraconazole, a serum trough of 0.5-4 mg/L (measured by HPLC) is recommended for prophylaxis 335 
(AII [efficacy], BII [safety]) and a trough of 1-4 mg/L is recommended during the treatment of IA (AII 336 
[efficacy], BII [safety]) [120-125]. Itraconazole has an active metabolite, OH-itraconazole that is 337 
present in similar (1:1) concentrations as the parent itraconazole compound when patients are at 338 
pharmacokinetic steady state. OH-itraconazole concentrations may be reported separately when 339 
samples are analysed ďǇ HPLC or LC/M“/M“, ďut ǁill iŶĐluded iŶ the oǀerall report of ͞itraĐoŶazole͟ 340 
concentrations if samples are analysed by bioassay [126, 127]. Therefore, the target range for 341 
itraconazole is higher when reported by bioassay (i.e. 3-17 mg/L) but may vary by lab depending on 342 
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the reference standards used. Samples should be acquired within 5-7 days of starting therapy. Repeat 343 
TDM is recommended the following week to confirm the patient remains in the therapeutic range, and 344 
repeated thereafter as ĐliŶiĐallǇ iŶdiĐated if there are ĐhaŶges iŶ the patieŶt͛s ĐliŶiĐal ĐoŶditioŶ, 345 
concomitant medications known to interact, or suspected toxicity (Table 22). Steady-state 346 
concentrations can often be predicted from earlier (non-steady) state samples through 347 
pharmacokinetic models or computerized dosage-assistance. In centres where these tools are 348 
available, sampling before day 5-7 may be preferable. 349 
 350 
Voriconazole 351 
A plasma trough concentration of 1-5.5 mg/L is considered adequate for most patients receiving 352 
voriconazole prophylaxis or treatment (AII, safety and efficacy) [128-133]. However, a trough of 2-353 
6 mg/L (AII, safety and efficacy) is recommended in patients treated for severe infections (multifocal 354 
or disseminated disease, CNS infections, infection with pathogen with elevated MICs, e.g. an MIC of 2 355 
ml/L) [130, 131]. TDM is strongly recommended in children due to the much higher rates of drug 356 
elimination and potential for underdosing, especially with the lower voriconazole doses recommended 357 
in the past (AII) [134, 135]. Plasma levels should be monitored between 2-5 days after initiation of 358 
therapy, and repeated the following week to confirm the patient remains in the therapeutic range. 359 
Repeated monitoring is indicated until steady state level in the therapeutic range is confirmed, if there 360 
are ĐhaŶges iŶ the patieŶt͛s ĐliŶiĐal ĐoŶditioŶ, ĐoŶcomitant medications, or suspected toxicity (Table 361 
23). 362 
 363 
Posaconazole 364 
For patients receiving posaconazole suspension, a plasma trough of >0.7 mg/L is recommended during 365 
prophylaxis (BII efficacy) [136, 137]; and a trough of >1 mg/L is recommended if the patient is receiving 366 
treatment for suspected or documented IA (AII efficacy) [138]. Currently, no studies have defined an 367 
upper plasma target that is associated with toxicity, although pharmacokinetic studies supporting the 368 
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registration of the new posaconazole tablet and intravenous formulations with the EMA used a 369 
provisional cut-off of 3.75 mg/L [139-141]. Posaconazole plasma trough levels should be monitored on 370 
day 5 of therapy or soon thereafter, and repeated as clinically indicated. 371 
For most patients prescribed posaconazole, we recommend using the newer tablet formulation (or 372 
intravenous formulation, if tablet formulation is contraindicated) rather than the suspension (AII), as 373 
tablets are more likely to consistently achieve target plasma levels and are less affected by GI-374 
dependent drug interactions [139]. Currently, there is limited evidence to suggest that all patients 375 
receiving posaconazole tablets or IV formulation for prophylaxis require routine TDM; however, our 376 
opinion is that when treating suspected or documented Aspergillus infections, TDM could still be useful 377 
if the pathogen has elevated MICs, is unresponsive to treatment, or in the event of unexplained toxicity 378 
(BIII). Until further data are available, we recommend using TDM monitoring strategies and plasma 379 
trough targets as detailed above suggested for the suspension formulation (Table 24). 380 
 381 
Isavuconazole 382 
Although dose-response and plasma concentration-response relationships for isavuconazole have 383 
been reported in animal models, limited data are currently available to define a target therapeutic 384 
range or support the need for routine TDM for this agent [142]. Our opinion is that TDM could still be 385 
useful in the clinical assessment or monitoring of patients receiving isavuconazole therapy (CIII) if 386 
patients are unresponsive to treatment, have unexpected toxicity, pharmacokinetic drug-drug 387 
interactions, or if isavuconazole is being used to treat pathogens with elevated MICs or sanctuary sites 388 
such as the CNS. In the absence of well-defined therapeutic targets, documentation of a plasma trough 389 
in the range of 2-3 mg/L (mean concentration range from phase II/III clinical studies) after day 5 390 
(including loading doses) suggests adequate drug exposure (Table 25). 391 
 392 
Flucytosine 393 
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In rare circumstances, flucytosine may be used in combination with other antifungals for the treatment 394 
of triazole-resistant Aspergillus spp. In this scenario, weekly measurement of peak serum 395 
concentrations 2 hours following an oral dose (AII) are needed to confirm that peak concentrations 396 
are 50-100 mg/L in order to reduce the risk of toxicity. Trough concentrations required for efficacy are 397 
unknown but a level of 25-50 mg/mL is recommended based upon experience from cryptococcosis 398 
[143, 144]. 399 
 400 
Hospital Environment 401 
Standards for the hospital environment in immunosuppressed adults and children requires special 402 
attention. Patients need to be segregated from construction or renovation (AIIh), potted plants (BII), 403 
aŶd floǁers iŶ ǁards aŶd iŶ patieŶts͛ rooŵs (CIII) [145-150]. Published data support the 404 
recommendation to accommodate patients in special hospital rooms with positive air pressure and 405 
HEPA filters (BII) or laminar airflow (BIIh). However, data were with historical controls, underpowered, 406 
or described by multivariate analysis describing high-risk situations for IA [151-154]. Protective masks 407 
for patients are proven not to be effective outside of the protected area (CII) [155]. Filters for water 408 
supply, especially in showers, are recommended (BII) [156-160]. No data are available to support 409 
regular environmental air sampling to prevent infections. However, indoor sampling is advisable to 410 
monitor filter efficacy (BIII) [161, 162]. 411 
 412 
Treatment Strategies 413 
Two strategies are accepted for managing patients with haematological malignancy at risk for IA: 1) 414 
the patient receives primary prophylaxis or 2) the patient receives no prophylaxis but is monitored at 415 
least twice weekly using biomarkers. The decision between the two strategies depends on local 416 
epidemiology, access to rapid diagnostics and patient characteristics. Breakthrough fungal diseases 417 
may appear through either symptoms or a disease-identifying biomarker or imaging result. Figure 1 418 
depicts a consensus algorithm for patient management. 419 
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 420 
Primary Prophylaxis 421 
At least three studies describe a number of patients who succumbed with IA missed prior to death 422 
[163-165]. Although diagnostic procedures improved since then, they are not satisfactory. For this 423 
reason, patients known to be at high risk for IA may receive primary prophylaxis, especially patients 424 
with profound and prolonged neutropenia or with active graft-versus-host disease (GvHD) (Table 26). 425 
 426 
Aspergillosis in Haematological Malignancy and Haematopoietic Stem Cell Transplantation 427 
In patients treated for haematological diseases, prolonged severe neutropenia is the most important 428 
risk factor for the development of IA. T cell depleted grafts, glucocorticosteroids and other immune 429 
suppressive drugs have been identified as further risk factors for IA in the later course after HSCT, even 430 
in non-neutropenic patients [166]. In fact, up to two thirds of patients with IA diagnosed after 431 
allogeneic HSCT are not neutropenic [167], and the median time of diagnosis of IA after allogeneic 432 
HSCT is 82 days (range, 3 - 6542 days) [168]. 433 
 434 
Treatment 435 
Providing a definite diagnosis of IA is a continuously challenging endeavour for clinicians. The 436 
EORTC/MSG definitions are only designed for clinical studies. For clinical decision-making, these 437 
definitions could have a deleterious outcome since confirmation of a proven or probable diagnosis 438 
would delay the start of therapy [169]. Any patient at risk considered by the responsible clinician as 439 
having IA should receive antifungal therapy (AIII) (Tables 27-28). Physicians should consider IV to oral 440 
switch in stable and PK-reliable patients. Treatment duration depends on clinical response and on 441 
immune reconstitution or recovery from GvHD. Good partial or complete remission requires no 442 
persistent clinical, including imaging (scarring allowed) or microbiological evidence of disease. The 443 
range of the duration of treatment (3 to >50 weeks) is huge and the evidence base to support any 444 
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particular recommendation is weak [170-173]. Close monitoring (e.g. non-enhanced CT or, if 445 
applicable, biomarkers) is suggested once antifungal treatment is discontinued. 446 
Additional adjunctive therapy such as the administration of G-CSF or G-CSF-primed granulocyte 447 
infusions (data mainly from paediatric populations) received only a weak supportive recommendation 448 
(CIII). In refractory cases, G-C“F ;or IFNγͿ has iŵŵuŶoŵodulatorǇ effeĐts [174-179]. No controlled trials 449 
have been performed and only anecdotal data with small numbers of patients exist. Persistent 450 
neutropenia is related with treatment failure, recovery from neutropenia enhances the efficacy of 451 
antifungal agents. A recent Cochrane review investigating the efficacy of granulocyte transfusions 452 
indicated no mortality difference for any kind of infection in patients with neutropenia [180]. 453 
 454 
Fever-driveŶ ;͞EŵpiriĐ͟Ϳ, aŶd DiagŶosis-driveŶ ;͞Pre-eŵptive͟Ϳ Therapy 455 
As an alternative to prophylaxis, patients could receive the classical empirical administration of 456 
antifungal agents during fever refractory to broad-spectrum antibacterial agents. Empiric treatment is 457 
defined as a fever-driven treatment approach. Patients who would qualify for this approach are 458 
patients receiving induction or remission chemotherapy for acute leukaemia or MDS or conditioning 459 
chemotherapy for haematopoietic stem cell transplantation. Empiric antifungal treatment is expected 460 
to reduce morbidity [181-186] and mortality [187, 188] (Table 29). The duration of empiric antifungal 461 
treatment is set by the following rules applied in randomized clinical trials: If the patient is afebrile and 462 
has no active infection or infiltrates, then antifungal therapy can be discontinued after recovery of 463 
leukocyte counts [188-190]. Today, antifungal stewardship may warrant clinical trials on empiric 464 
treatment duration, but no such trial has been conducted so far. 465 
Pre-emptive treatment is a diagnosis driven strategy. In most cases, it is defined by positive GM testing. 466 
However, chest CT with pulmonary infiltrates could apply as well. The use of BDG and PCR testing as 467 
alternative biomarkers for galactomannan have considerable merit [191, 192], though BDG is not 468 
specific for Aspergillus disease. In haematological patients, false positive BDG often results from 469 
contaminated infusions [193-196]. Very few authors wait for Aspergillus-associated suggestive 470 
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radiological signs including nodule, halo sign, wedge-shaped area of consolidation, or – late in the 471 
course of invasive aspergillosis – the air crescent sign, before starting antifungal treatment. Treatment 472 
choices are as recommended in targeted treatment. 473 
 474 
Adult Patients without Haematological Malignancy 475 
Epidemiology 476 
Approximately 43-80% of the cases of IA appear in patients without a haematological malignancy [52, 477 
197-200], although these patients are rarely included in the seminal studies of antifungals [170, 171, 478 
173]. The proportion of these patients is even increased when exposed to spore concentrations of >25 479 
cfu/m3 in hospital air [201-204]. The non-haematological populations at risk for IA include solid organ 480 
transplant recipients (SOT), patients treated with prolonged high dose glucocorticosteroids, or with 481 
other immunosuppressants, patients with advanced AIDS or neoplasia, COPD, liver failure, liver 482 
cirrhosis, influenza as well as critically ill patients requiring ICU admission [52, 197-199, 205-208]. 483 
These patients frequently do not fulfil the EORTC/MSG criteria for invasive aspergillosis [169]. 484 
Confirmation of diagnosis may be delayed resulting in high mortality rates. At the same time drug-drug 485 
interactions and toxicity can occur more frequently compared to haematological patients [52]. 486 
Physicians need to be aware of the specific risk factors, clinical manifestations and management 487 
challenges in order to improve outcome. In SOT recipients the average incidence of IA ranges from 0.1 488 
to 11.6% [209, 210], with the highest risk in small bowel (11.6%) and lung (8.6%) transplant recipients, 489 
followed by patients receiving liver (4.7%), heart (4.0%), pancreas (3.4%), and kidney (1.3%) grafts 490 
[209-211]. Half the cases will occur in the first three months after transplantation, in patients with 491 
post-surgical risk factors. Late aspergillosis is more common in elderly recipients, and patients with 492 
pronounced immunosuppression due to rejection or post-transplant neoplasia or chronically impaired 493 
graft function [210, 212]. With the exception of lung transplantation, in which universal prophylaxis is 494 
still common, antifungal prophylaxis will target SOT recipients with additional risk factors [211]. Risk 495 
factors for early IA in all SOT recipients – Including heart transplants – comprise renal failure requiring 496 
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replacement therapy, re-intervention, CMV disease, and high environmental exposure to mould 497 
spores [211, 213-215]. In liver transplantation, high model for end-stage liver disease (MELD) score, 498 
transplantation in fulminant hepatic failure, high intraoperative transfusion needs or re-499 
transplantation are considered indications for post-surgical prophylaxis [216-224]. In lung transplant 500 
recipients, risk factors include previous respiratory tract colonization with Aspergillus, single lung 501 
transplant, CMV disease and acquired hypogammaglobulinaemia [225-227]. In kidney transplantation 502 
risk factors include COPD, delayed graft function, bloodstream infection, and acute graft rejection 503 
[228] and an >1.25 mg/kg/day average dose of prednisone [229]. Finally, some polymorphisms in 504 
defence genes have also been suggested to increase risk in transplant recipients [230, 231]. 505 
The incidence of IA in HIV patients has decreased since the advent of new antiretroviral therapy (2.2 506 
cases per 10,000/year), but mortality remains high (38%) [232]. IA typically appears in patients with 507 
low CD4 counts and associated conditions such as neutropenia, advanced cirrhosis, liver 508 
transplantation or glucocorticosteroid therapy [233-241]. As in other non-haematological populations, 509 
EORTC/MSG criteria only detect half of the IA cases diagnosed among HIV-infected patients [232] and 510 
in a recent series of autopsies of AIDS patients, only 12% of the patients with IA had been diagnosed 511 
ante mortem [242] (Table 30). 512 
IA may affect 0.3% of patients with liver cirrhosis [243]. Both acute liver failure and advanced cirrhosis, 513 
mainly alcoholic hepatitis treated with glucocorticosteroids, have been recognized as risk factors for 514 
IA [205, 244-246]. A low level of clinical suspicion explains that 53% of the cases of IA in cirrhotic 515 
patients are only recognized post-mortem [247] and that liver disease is independently associated with 516 
IA-related mortality [199, 248]. 517 
IA has also been described in apparently immunocompetent patients in a critical condition as a 518 
complication of ARDS, COPD, influenza, pneumonia, burns, severe bacterial infection, surgery, and 519 
malnutrition. Incidence is 4-6/1,000 ICU admissions and the mortality is higher than 70% in most series 520 
[245, 249-252]. Glucocorticosteroid treatment was the major host factor [253, 254] and as in cirrhotic 521 
or HIV positive patients delayed diagnosis is common [255, 256]. COPD patients requiring 522 
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glucocorticosteroids represent a group with especially high mortality [249, 257 , 258]. Risk factors 523 
include admission to ICU, chronic heart failure, and antibiotic treatment and, above all, the cumulative 524 
dose of glucocorticosteroids [257]. 525 
Pulmonary and CNS aspergillosis predominates in these populations, but disseminated disease, 526 
fulminant and atypical forms may occur [203, 214, 225, 251, 259-267]. The sensitivity of most 527 
diagnostic methods is lower in non-haematological patients. Isolation of Aspergillus from respiratory 528 
cultures has a much lower positive predictive value so over-diagnosis has to be prevented [197, 268-529 
272]. Regarding imaging findings, angioinvasive presentation included in the EORTC/MSG criteria is 530 
uncommon in this setting [273]. Airway invasive radiological presentation was present in 37% of heart 531 
transplant recipients and was associated with delayed diagnosis and poorer prognosis [214, 274]. In 532 
COPD and HIV-positive patients, the most common radiological presentation was an alveolar infiltrate 533 
[273, 275, 276]. Experience with biomarkers and PCR is still scarce in these populations, but the 534 
combination of at least two different methods appears to be the best diagnostic approach [277-285] 535 
(Table 31). 536 
 537 
Treatment 538 
Despite no comparative studies of antifungal therapy in non-haematological patients voriconazole 539 
remains the first option, since it has been related to reduced mortality [216, 286-288] (Table 32). 540 
Combination therapy is uncommon, although retrospective data was encouraging in SOT recipients 541 
[289]. The risks of drug-drug interactions and toxicity are very important in these populations and TDM 542 
is advisable [290-295]. In patients with liver insufficiency, L-AMB is usually the first therapeutic option. 543 
Antifungal resistance is not a common problem despite prophylaxis [296, 297], although some cases 544 
have been reported [298-300]. Finally, immune reconstitution syndrome may occur after therapy 545 
initiation [301]. 546 
Most lung recipients receive antifungal prophylaxis. Targeted prophylaxis is preferred in the remaining 547 
SOT with risk factors [211, 213, 302-305]. However, significant variation in practice has been noted 548 
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[221, 304, 306, 307]. In order to avoid drug-drug interactions and toxicity, echinocandins or inhaled 549 
amphotericin are preferentially used [308-311], although voriconazole has also demonstrated its 550 
efficacy and safety in this setting [217, 220, 312-314]. Duration of prophylaxis is adjusted to the 551 
presence of risk factors and, with the exception of lung recipients, is usually limited to 3-4 weeks [215] 552 
(Table 33). 553 
 554 
Special Considerations in Children 555 
Presenting symptoms, distributions and patterns of diseases and vulnerability to IA are similar 556 
between children and adults. However, differences exist in epidemiology and underlying conditions, 557 
usefulness of newer diagnostic tools, pharmacology of antifungal agents and evidence from 558 
interventional phase III studies. Recommendations for paediatric patients are based on efficacy in 559 
phase II and III trials in adults, the availability of paediatric pharmacokinetic data, safety data and 560 
supportive efficacy data. In addition, regulatory approval is considered as well. Therapeutic drug 561 
monitoring is always recommended when mould-active azoles are used as prophylaxis or treatment. 562 
PriŵarǇ aŶtifuŶgal prophǇlaǆis ŵaǇ ďe iŶdiĐated iŶ paediatriĐ patieŶts at ͚high risk͛ for deǀelopiŶg 563 
invasive fungal diseases, and specifically IA. An incidence rate of IFDs of шϭϬ% is usuallǇ ĐoŶsidered as 564 
high risk. High-risk populations include children with de novo or recurrent leukaemia (e.g. AML, ALL 565 
depending on treatment protocol), bone marrow failure syndromes with profound and persistent 566 
neutropenia (e.g. MDS, VSAA), allogeneic HSCT recipients, patients with chronic granulomatous 567 
disease and those undergoing lung transplantation. For patients with haematological disorders, the 568 
mould-active oral azoles are the first choice to prevent IA in children, although neither itraconazole 569 
nor posaconazole are licensed for use in patients <18 years of age. Due to the lack of paediatric data, 570 
recommendations for lung and high-risk liver transplant patients correspond to those given for adults 571 
[213, 315]. Secondary prophylaxis to prevent recurrence of IA when risk factors are persisting is 572 
recommended with an antifungal targeted at the previous Aspergillus species, which caused the first 573 
episode (see below and Table 34). 574 
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Diagnostic procedures used in children are not different from those used in adults but their 575 
performance may differ. Suggestive abnormalities (e.g. halo sign, air crescent sign) on CT-chest as 576 
described in adults are less common in children in which non-specific masses or infiltrates predominate 577 
[316-318]. The GM test on blood and BAL samples has a similar sensitivity and specificity profile 578 
compared to adults [319-327]. The BDG test is not specific for Aspergillus and is not validated in 579 
children. Higher baseline levels are reported in healthy children and therefore the cut-off is yet 580 
unknown [328-332]. 581 
General management principles of IA are consistent with those in adults and include prompt initiation 582 
of antifungal therapy, control of predisposing conditions (e.g. reduction or discontinuation of 583 
glucocorticosteroids in immunosuppressed, administration of colony-stimulating factors in 584 
neutropenic patients), and surgical interventions on a case by case basis using a multidisciplinary 585 
approach. Voriconazole is recommended as the first line agent to treat IA in all children except 586 
neonates (AIIt). L-AmB is first choice for neonates (AIII) and may replace voriconazole as first line 587 
treatment in areas or institutions with a high prevalence of azole-resistant A. fumigatus. Upon 588 
diagnosis of invasive pulmonary aspergillosis, thorough evaluation for further sites of infection is 589 
required and should include the CNS. The optimal duration of therapy is determined by the resolution 590 
of all signs and symptoms and reversal of the underlying deficit in host defences. For salvage therapy 591 
and breakthrough infections, a switch to a different class of antifungals is recommended [123, 132, 592 
138, 170, 171, 177, 333-341] (Table 35). 593 
If a fever-driven (empiric) strategy is used in at risk paediatric haematological patients, caspofungin or 594 
L-AmB are recommended until resolution of fever and neutropenia [342-344]. Treatment 595 
recommendations for a diagnosis-driven (pre-emptive) strategy correspond to those made for 596 
targeted treatment [185, 186, 345, 346]. 597 
 598 
Secondary Prophylaxis 599 
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Secondary prophylaxis is a treatment strategy to prevent recurrence of IA during a subsequent risk 600 
period of immunosuppression. Patients with a history of IA previously successfully treated with 601 
antifungals entering a subsequent risk period of immunosuppression, e.g. allogeneic HCT (early phase), 602 
chemotherapy resulting in severe neutropenia (i.e. <500/µL and at least for 7 days), acute GvHD >I° or 603 
extensive chronic GvHD, or T-cell suppressing therapy, including steroids, are at risk. Agents for 604 
secondary prophylaxis are listed in table 36. 605 
 606 
Treatment of Refractory Disease 607 
Refractory IA is defined as progression of disease and should be differentiated from stable disease 608 
[349]. Patients with radiological evidence of progression and persisting elevated GM have a very high 609 
probability of treatment failure resulting in death. Assessment of response should use composite 610 
outcome parameters including clinical, radiological, and mycological criteria. Radiological progression 611 
following or closely preceding neutrophil recovery should be carefully evaluated and is not necessarily 612 
indicative of failure. Keeping this in mind, assessing response 2 weeks after treatment initiation 613 
generally allows predicting the response, especially recognizing oncoming failure [350]. In case of GM 614 
negative IA, early assessment of response may be difficult and could require a longer time of therapy. 615 
If failure ascertained, look for poor vascular supply (i.e. sinusitis requiring surgical treatment), 616 
microbiological confirmation is recommended since identification of the fungus at the species level is 617 
pivotal. If a viable organism is recovered, susceptibility testing is recommended, especially regarding 618 
azole resistance. On the other hand, azole concentration should be monitored as well (see chapters 619 
on resistance and therapeutic drug monitoring within this guideline) [38, 349, 351-359]. The choices 620 
of antifungal agents in refractory disease are listed in table 37. 621 
 622 
Chronic Pulmonary Aspergillosis (CPA) 623 
CPA is an indolent destructive disease of the lungs usually complicating other pulmonary conditions 624 
occurring in non- or mildly immunocompromised patients [360, 361]. Its manifestations include 625 
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chronic cavitary pulmonary aspergillosis (CCPA), which if left untreated may progress to chronic 626 
fibrosing pulmonary aspergillosis (CFPA), Aspergillus nodule and single aspergilloma [11, 362]. 627 
Subacute invasive pulmonary aspergillosis (previously chronic necrotizing pulmonary aspergillosis) is 628 
also a cavitating destructive lung disease usually found in moderately immunocompromised patients 629 
which progresses more rapidly, typically over 1 to 3 months. The diagnosis of CPA requires a 630 
combination of characteristics: one or more cavities with or without a fungal ball present or nodules 631 
on thoracic imaging, either direct evidence of Aspergillus infection (culture or microscopy from biopsy) 632 
or an IgG antibody response to Aspergillus spp. and exclusion of alternative diagnoses (especially 633 
mycobacterial infection), all present for at least 3 months [11, 363]. Over 90% of patients have 634 
circulating Aspergillus antibody (precipitins) (AII) [364]. A positive culture of A. fumigatus respiratory 635 
tract secretion (BAL, bronchoscopy aspiration) is not diagnostic because many different pathologies 636 
are attributable to the fungus, and it may be an airway colonizing fungus or a plate contaminant in the 637 
laboratory. 638 
If a fungal ball is seen, then only a positive test of Aspergillus IgG or precipitins confirms pathogenicity. 639 
Patients may have CPA and other infections concurrently (see below). 640 
The distinctive hallmark of CCPA is new and/or expanding cavities with thick or thin walls in those with 641 
chronic lung disease. An intracavitary fungal ball may be present, often with pleural thickening and 642 
extensive parenchymal destruction and/or fibrosis. Patients may have CPA and other infections 643 
concurrently, especially bacterial including Pseudomonas aeruginosa infection or tuberculosis and 644 
non-tuberculous mycobacterial infection. Aspergillus nodules, which may be single or multiple, may 645 
mimic malignancy as well as nodules seen in rheumatoid arthritis, coccidioidomycosis, tuberculosis, 646 
non-tuberculous mycobacterial infection and – rarely – actinomycosis or rheumatoid arthritis. 647 
Typically, Aspergillus nodules appear rounded, some with low attenuation or cavitation within. Some 648 
are spiculated, a common feature of carcinoma [362]. 649 
If technically feasible single aspergilloma should be surgically removed, preferably via video-assisted 650 
thoracic surgery technique with due consideration to risks as recommended [365]. Long term oral 651 
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antifungal therapy is strongly recommended in patients with CCPA, partly to reduce general and 652 
respiratory symptoms [366, 367], but also to minimise haemoptysis and prevent lung destruction and 653 
fibrosis (AII) itraconazole or voriconazole are effective for CCPA (AIII) [11]. Oral posaconazole is a 654 
potential alternative treatment (BII) [11]. Six months of therapy is the recommended minimum (AI) 655 
[11]. Relapse is common after discontinuation. Intravenous therapy for CPA is useful in patients who 656 
fail or are intolerant of triazoles or have triazole resistant A. fumigatus. Prednisolone may be 657 
considered for underlying symptom control only if patients are adequately treated with antifungals. 658 
Mild and moderate haemoptysis usually responds to tranexamic acid; severe haemoptysis should be 659 
arrested with bronchial artery embolization (Table 38). 660 
 661 
Conclusions 662 
This executive summary is a comprehensive guideline covering many aspects of Aspergillus diseases. 663 
It provides guidance for clinicians on prevention of disease, diagnostic procedures, resistance issues 664 
and treatment of IA as well as chronic pulmonary aspergillosis. The guideline group intends to provide 665 
additional publications supporting the rationale of recommendations given. 666 
Finally, the guideline group provides comprehensive tables explaining various options for specific 667 
situations.  668 
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Table 1. Strength of recommendation and quality of evidence 669 
Strength of 
Recommendation 
(SoR) 
Definition 
Grade A Societies strongly support a recommendation for use 
Grade B Societies moderately support a recommendation for use 
Grade C Societies marginally support a recommendation for use 
Grade D Societies support a recommendation against use 
Quality of Evidence 
(QoE) 
Definition 
Level I Evidence from at least 1 properly* designed randomized, controlled trial 
(orientated on the primary endpoint of the trial) 
Level II Evidence from at least 1 well-designed clinical trial (incl. secondary 
endpoints), without randomization; from cohort or case-controlled 
analytic studies (preferably from >1 centre); from multiple time series; or 
from dramatic results of uncontrolled experiments 
Level III Evidence from opinions of respected authorities, based on clinical 
experience, descriptive case studies, or reports of expert committees 
Added Index Source of Level II Evidence 
r Meta-analysis or systematic review of RCT 
t Transferred evidence i.e. results from differeŶt patieŶts͚ Đohorts, or 
similar immune-status situation 
h Comparator group: historical control 
u Uncontrolled trials 
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a For published abstract presented at an international symposium or 
meeting 
* poor quality of planning, inconsistency of results, indirectness of evidence etc. would lower the 
SoR 
 670 
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Table 2. Recommendations for imaging and bronchoalveolar lavage 671 
Population Intention Intervention* SoR QoE Comment Ref. 
Neutropenia, fever or clinical 
symptom of pneumonia, empiric 
antibiotics, failing to achieve 
defervescence, e.g. FUO 
To detect pulmonary 
infiltrates 
Chest CT and 
thin section 
multi-
detector CT 
(MDCT) 
A II Within 12-24h after the beginning of fever, dose 
optimization recommended 
[21, 31, 
35, 368] 
Haemoptysis To identify vessel 
occlusion 
Chest angio-
CT / 
pulmonary CT 
angiography 
B II 
 
[24-26] 
Haemoptysis To identify vessel erosion Chest angio-
CT / 
pulmonary CT 
angiography 
A II 
 
[24-26, 
369, 370] 
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Any To identify possible 
underlying fungal or 
other infectious disease 
BAL A II  [21, 49-
54] 
Any To obtain appropriate 
specimens for 
microscopy, culture and 
PCR 
CT-guided 
BAL 
A III 
 
[55, 56] 
*, Diagnostic tests are interventions; SoR, Strength of recommendation; QoE, Quality of evidence; FUO, fever of unknown origin; CT, computed tomography; 672 
BAL, bronchoalveolar lavage; PCR, polymerase chain reaction 673 
  674 
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Table 3. Microscopic examinations 675 
Popula
tion 
Intention Intervention SoR QoE Comment Ref. 
Any To identify fungal 
elements in 
histological sections 
and stains 
Histological examination 
Goŵori͛s ŵetheŶaŵiŶe 
silver stain 
Periodic acid-Schiff 
A III Histopathology is an essential investigation 
Inability to definitively distinguish other filamentous fungi 
GMS: removes cellular background; more sensitive to hyphal 
elements 
PAS: advantage of counter stain to check cellular detail 
[80, 371-
373] 
Any To identify fungal 
elements in 
histological sections 
and stains 
Fluorescent dyes: 
Calcofluor white™, Uvitex 
2B, Blancophor™ 
A II Not specific to Aspergillus but high sensitivity and the 
micromorphology may provide info on the fungal class (e.g. 
Aspergillus: typically dichotomous and septate, Mucorales: 
pauci-septate and 90° angle branching, yeast: budding) 
Rapid turnaround time 
Broad applicability 
May be applied to frozen sections, paraffin-embedded tissue 
[374-
378] 
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Any To identify fungal 
elements in 
histological sections 
and stains 
Immunohistochemistry 
Monoclonal antibody WF-
AF-1 or EB-A1 
In situ hybridization 
B II Have the potential to provide genus and species specific data 
Commercially available monoclonal antibodies 
WF-AF-1 is specific for A. fumigatus, A. flavus, and A. niger 
Time consuming and not broadly available 
[374-
378] 
Any To identify fungal 
elements in fresh 
clinical specimens 
(e.g. BAL) 
Application of fluorescent 
dyes Calcofluor white™ or 
Uvitex 2B or Blancophor™ 
A II Essential investigation 
Not specific for Aspergillus species 
High sensitivity 
Rapid turn-around time 
Broad applicability 
No species identification but the micromorphology may provide 
info on the fungal class (e.g. Aspergillus: typically dichotomous 
and septate, Mucorales: pauci-septate and 90° angle branching, 
yeast: budding) 
[80, 373, 
379] 
SoR, Strength of recommendation; QoE, Quality of evidence; BAL, bronchoalveolar lavage; HE, haematoxylin-eosiŶ; GM“, Goŵori͛s ŵetheŶaŵiŶe silver 676 
stain; PAS, Periodic acid-Schiff; CNS, central nervous system 677 
  678 
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Table 4. Sample selection and pre-analytical respiratory sample treatment 679 
Population Intention Intervention SoR QoE Comment Ref. 
Any To achieve a 
homogenous sample of 
viscous samples such as 
sputum 
Liquefaction using a 
mucolytic agent, e.g. 
Pancreatin®, Sputolysin®, 
or using sonication and 
1,4-dithiothreitol 
A III Essential investigation 
High volume sputum culture (entire sample) shown to 
significantly increase recovery 
[81, 380] 
Any To achieve optimal 
recovery of Aspergillus 
from BAL by 
centrifugation and 
investigation of the 
sediment 
Centrifugation of BALs or 
bronchial aspirates 
A III Essential investigation 
Isolation of Aspergillus dependent on volume cultured 
[81] 
SoR, Strength of recommendation; QoE, Quality of evidence; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction 680 
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Table 5. Culture and Aspergillus species identification 682 
Popula
tion 
Intention Intervention SoR QoE Comment Ref. 
Any Primary isolation from 
deep sites samples (e.g. 
biopsies, blood, CSF) 
Culture on SDA, BHI agar, 
PDA at 30ºC and 37ºC for 
72 h 
A III Blood inhibits conidiation; BHI can help to recover some 
isolates; Isolation of several colonies or isolation of the 
same fungus from a repeat specimen enhance significance 
[81, 381, 
382] 
Primary isolation from 
non-sterile samples, e.g. 
sputum, respiratory 
aspirates 
Culture on SDA, BHI agar, 
PDA with gentamicin plus 
chloramphenicol at 30ºC 
and 37ºC for 72 h 
A III High volume sputum culture (entire sample) shown to 
significantly increase recovery; Quantitative cultures are 
not discriminative for infection or colonization 
Identification of species 
complex 
Macroscopic and 
microscopic examination 
from primary cultures 
A II Colony colour, conidium size, shape and septation. Colour 
of conidia and conidiophore and conidiogenesis (tease or 
tape mounts are preferred); Expertise needed for 
interpretation 
Identification of species 
complex (and species 
Culture on identification 
media at 25-30ºC, 37ºC 
A II 
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identification of A. 
fumigatus specifically) 
and 50ºC (2% MEA and 
Czapek-Dox Agar) and 
microscopic examination 
Thermotolerance test (growth at 50 °C for species 
confirmation of A. fumigatus) 
Identification at species 
level 
MALDI-TOF MS 
identification 
B II In house databases are often used to improve identification 
rates 
[383-386] 
Identification at species 
level 
Sequencing of ITS, beta-
tubulin and calmodulin 
A III Not necessary in organisms with typical growth, but in 
cases of atypical growth 
[387, 388] 
To study outbreaks Microsatellite and CSP 
analysis 
C II To study outbreaks (which in general may comprise more 
than one genotype) 
[389-391] 
B II To study colonisation patterns [392] 
SoR, Strength of recommendation; QoE, Quality of evidence; CSF, cerebrospinal fluid; SDA, Sabouraud dextrose agar; BHI, brain heart infusion; PDA, 
potato dextrose agar; MEA, malt extract agar; MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass spectometry 
identification; ITS, internal transcribed spacer; CSP, Cell surface protein 
  683 
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Table 6. Galactomannan testing in blood samples 684 
Population Intention Intervention SoR QoE Comment Ref. 
Patients with prolonged 
neutropenia or allogeneic stem 
cell transplantation recipients 
not on mould-active prophylaxis 
Prospective 
screening for IA 
GM in blood* A I Highest test accuracy requiring 2 consecutive samples with an 
ODI ш Ϭ.ϱ or retestiŶg the saŵe saŵple 
Prospective monitoring should be combined with HRCT and 
clinical evaluation 
[82, 
94, 
393-
397] 
Draw samples 
every 3-4 days 
C III 
Patients with prolonged 
neutropenic or allogeneic stem 
cell transplantation recipients on 
mould active prophylaxis 
Prospective 
screening for IA 
GM in blood* D II Low prevalence of IA in this setting with consequently low PPV 
of blood GM test 
Prophylaxis may have a negative impact on sensitivity of the 
test or the low yield may be due to decreased incidence of IA 
[398, 
399] 
Patients with a haematological 
malignancy 
• Neutropenic patients 
• Non-neutropenic 
patients 
To diagnose IA GM in blood*  
 
A 
B 
 
 
II 
II 
Significantly lower sensitivity in non-neutropenic patients [319, 
394, 
400, 
401] 
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ICU patients To diagnose IA GM in blood* C II Better performance in neutropenic than in non-neutropenic 
patients 
[89, 
402] 
Solid organ recipients To diagnose IA GM in blood* C II Low sensitivity, good specificity 
Most data for lung SOT 
[319, 
403, 
404] 
Any other patient To diagnose IA GM in blood* C II Piperacillin/tazobactam may no longer be responsible for false 
positive results according to recent studies 
Cross reactivity in case of histoplasmosis, fusariosis, 
talaromycosis (formerly: penicilliosis)False positive results 
reported due to ingestion of ice-pops, transfusions, antibiotics, 
Plasmalyt® infusion 
 
[401, 
405-
412] 
Cancer patients To monitor 
treatment 
GM in blood* A II  [85, 
359, 
413] 
 39 
SoR, Strength of recommendation; QoE, Quality of evidence; *, serum or plasma; GM, galactomannan; IA, invasive aspergillosis; ICU, intensive care unit; 685 
ODI, optical density index; PPV, positive predictive value; SOT, solid organ transplantation 686 
  687 
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Table 7. Galactomannan testing in samples other than blood 688 
Population Intention Intervention SoR QoE Comment Ref. 
Any To diagnose 
pulmonary IA 
To apply GM test on 
BAL fluid 
A II GM in BAL is a good tool to diagnose, optimal cut-off to positivity 
0.5 to 1.0 
[86, 414-
418] 
Any To diagnose 
cerebral IA 
To apply GM test on 
cerebrospinal fluid 
B II No validated cut-off [419, 420] 
Any To detect GM in 
tissue 
To apply GM test on 
lung biopsies 
B II Using a cut-off 0.5 resulted in a sensitivity of 90 % and a specificity 
of 95%; specimens need to be sliced, precondition for doing so is 
that sufficient material is available; dilution in isotonic saline 
[373, 421] 
SoR, Strength of recommendation; QoE, Quality of evidence; BAL, bronchoalveolar lavage; GM, galactomannan; IA, invasive aspergillosis 689 
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Table 8. ß-D-glucan assays 691 
Population Intention Intervention SoR QoE Comment Ref. 
Mixed population: adult ICU, 
haematological disorders, 
SOT 
To 
diagnose 
IFD 
Diagnostic 
assay 
C II 5 different assays 
Overall sensitivity of 77% and specificity of 85% 
Specificity limits its value in this setting 
[90, 
422] 
Screening 
assays 
C II Two or more consecutive samples: sensitivity: 65%; specificity: 93% 
Studies included once to thrice weekly. Varies with assay and cut-off: 
Wako assay sensitivity: 40-97%, specificity: 51-99% 
[90, 
422] 
Adult haematological 
malignancy and HSCT 
To 
diagnose 
IFD 
Diagnostic 
assay 
C II Overall sensitivity: 50-70%, specificity: 91-99% [193-
195, 
423-
428] 
ICU – mixed adult 
immunocompromised 
patients (haematology, SOT, 
To 
diagnose 
IA 
Diagnostic 
assay 
C II Overall sensitivity: 78 -85%, specificity: 36-75%, NPV: 85-92% 
Specificity increased at higher cut-off values 
[429, 
430] 
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cancer, immunosuppressive 
therapy, liver failure, HIV) 
ICU – mixed adult population: 
SOT, liver failure, 
immunosuppressed 
Screening 
assays 
C III Sensitivity: 91%, specificity: 58%, PPV: 25%, NPV: 98%. 
Positive mean of 5.6 days before positive mould culture 
High false positive rate in early ICU admission 
[431] 
Adult haematological 
malignancy and HSCT 
To 
diagnose 
IA 
Diagnostic 
assay 
C II Overall sensitivity: 57-76%, specificity: 95-97% [422, 
423, 
429] 
Screening 
assays 
C II Overall sensitivity: 46%, specificity: 97% 
Confirmation with GM increases specificity 
Data suggests BDG is unsuitable for ruling out diagnosis of IA 
SoR, Strength of recommendation; QoE, Quality of evidence; HSCT, haematopoietic stem cell transplantation; ICU, intensive care unit; SOT, solid organ 692 
transplantation; IFD, invasive fungal disease; PPV, positive predictive value; NPV, negative predictive value; GM, galactomannan; BDG, ß-D-glucan test; IA, 693 
invasive aspergillosis  694 
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Table 9. Lateral flow device antigen test for IA 695 
Population Intention Intervention SoR QoE Comment Ref. 
Haematological malignancy 
and solid organ transplant 
To diagnose IA LFD applied on BAL 
samples 
B II Retrospective study. Sensitivity and specificity of BAL LFD 
tests for probable IPA were 100% and 81% (PPV 71%, NPV 
100%), 5 pts with possible IPA had positive LFD, no proven IA 
[432] 
Haematopoietic stem cell 
transplantation 
To diagnose IA LFD applied on serum 
samples 
B II Prospective screening in 101 patients undergoing allogeneic 
HSCT 
[433] 
Immunocompromised 
patients 
To diagnose IA LFD applied on BAL 
samples 
B II Retrospective study. Sensitivities for LFD, GM, BDG and PCR 
were between 70 and 88%. Combined GM (cut off >1.0 OD) 
with LFD increased the sensitivity to 94%, while combined GM 
(cut off >1.0 OD) with PCR resulted in 100% sensitivity 
(specificity for probable/proven IPA 95-98%). 
[434] 
SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; BDG, ß-D-glucan test; BAL, bronchoalveolar lavage; GM, 696 
galactomannan; HSCT, haematopoietic stem cell transplantation; IFD, invasive fungal diseases; LFD, lateral device flow; NPV, negative predictive value; PCR, 697 
polymerase chain reaction; PPV, positive predictive value 698 
699 
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Table 10. PCR on bronchoalveolar lavage or cerebrospinal fluid 700 
Population Intention Intervention SoR QoE Comment Ref. 
Patients undergoing  
allogeneic stem cell 
transplantation 
recipients not on 
mould-active 
prophylaxis 
To diagnose IA BAL PCR B II  [435] 
Patients with 
pulmonary infiltrates 
and haematological 
malignancies and 
prolonged 
neutropenia 
To diagnose IA BAL PCR B II Methodically different in-house assays, better performance in 
patients without antifungal treatment, PCR and galactomannan: 
increases specificity 
[359, 
415, 
434, 
436-
456] 
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ICU patients, mixed 
populations 
To diagnose IA BAL PCR B II Commercially available Aspergillus PCR assays with good 
performance data. 
[81][41
4][454]
[457][4
58][45
9] 
Patients with 
haematological 
malignancies 
To diagnose CNS 
aspergillosis or 
meningitis 
CSF PCR B II 113 CSF samples from 55 immunocompromised patients 
sensitivity 100%, specificity 93% (retrospective) 
[419, 
460-
463] 
SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis ; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction; ICU, 701 
intensive care unit; CNS, central nervous system; CSF, cerebrospinal fluid. 702 
  703 
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Table 11. PCR on whole blood, serum or plasma 704 
Population Intention Intervention SoR QoE Comment Ref. 
Patients with 
haematological 
malignancies 
To diagnose IA PCR on blood 
samples 
B II 
Meta-analysis: 16 studies PCR single positive test: Sensitivity: 88%, 
specificity: 75%; PCR 2 consecutive positive tests: Sensitivity: 75%, 
specificity: 87% 
[464] 
To diagnose IA PCR on serum 
samples 
97% of protocols detected threshold of 10 genomes/ml serum volume 
>0.5 ml, elution volume <100 µl, sensitivity: 86%; specificity: 94% 
[465] 
To diagnose IA PCR on whole blood 
samples 
First blood PCR assay to be compatible with EAPCRI recommendations, 
fever driven: Sensitivity: 92%, specificity: 95%, negative PCR result to be 
used to rule out IA 
[466] 
Haematopoietic 
stem cell 
transplantation 
To diagnose IA Prospective 
screening PCR on 
whole blood 
samples 
B II Combination of serum and whole blood superior [94-
97] 
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To diagnose IA Prospective 
screening PCR on 
blood samples 
B II Addition of GM and PCR monitoring provides greater accuracy, PPV 50-
80%, NPV 80-90% 
[98] 
To diagnose IA PCR and GM in BAL A II  [396] 
SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; PCR, polymerase chain reaction; EAPCRI, European Aspergillus PCR 705 
Initiative; GM, galactomannan, PPV, positive predictive value; NPV, negative predictive value; BAL, bronchoalveolar lavage 706 
  707 
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Table 12. Molecular diagnostics on biopsies 708 
Population Intention Intervention SoR QoE Comment Ref. 
Biopsy with 
visible 
hyphae 
To detect and 
specify a fungus 
Broad range PCR  A II High sensitivity (> 90 %) and high specificity (99 %); various 
molecular based techniques available 
[373, 
467] 
Biopsy with 
no visible 
hyphae 
To detect and 
specify a fungus 
Broad range PCR  C II Sensitivity (57 %) and specificity (96 %); ability to distinguish 
other fungi; performance only in addition to other tests 
[373, 
467] 
Biopsy with 
visible 
hyphae 
To detect and 
specify a fungus 
Broad range PCR on wax 
embedded specimens 
A II TaKaRa DEXPAT kit and QIAamp DNA mini kit detected less 
than 10 conidia/sample 
[468, 
469] 
Any To detect and 
specify a fungus 
Fresh tissue samples B II Aspergillus PCR performance analysis yielded 
sensitivity/specificity  rates of 86% / 100% (79 patients, 
retrospective study) 
[58] 
SoR, Strength of recommendation; QoE, Quality of evidence; PCR, polymerase chain reaction  709 
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Table 13. Storage of original samples and isolates 710 
Population Intention Intervention SoR QoE Comment Ref. 
Any To prevent loss of 
viability of Aspergillus 
in clinical samples, and 
to reflect the original 
fungal content 
Clinical samples for culture - 
short-term storage: 4°C to 
prevent loss of viability and to 
reflect the original fungal 
content 
A III  [98, 381] 
To prevent 
degradation of 
biomarkers, e.g. GM in 
serum or BALs or 
bronchial washes 
Complete assay soon after 
delivery to laboratory. Avoid 
short or long-term storage of 
serum at 4°C 
A I GM in serum degrades with short-term and long-term 
storage at 4°C; BAL fluid GM ODI remain stable; testing of 
pos./neg. serum and BAL fluid pools showed no decline 
in GM index over 11 months at -20°C 
[80, 371-
373, 
395] 
Short-term 
maintenance of 
Aspergillus isolates 
Repeated sub-culture A I Viability maintained for several years by frequent sub-
culture; Transfer once a month; Maintain at average 
ambient room temperature 
[98, 381] 
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Long-term 
preservation of 
Aspergillus isolates 
Water storage/storage under 
mineral oil/silica gel 
storage/freeze-drying freezing 
(-80°C/ceramic beads/liquid 
nitrogen) 
A I Long-term storage means storage periods of 5 years or 
longer; No further transfers required during this period 
SoR, Strength of recommendation; QoE, Quality of evidence; GM, galactomannan; BAL, bronchoalveolar lavage; ODI, optical density index 711 
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Table 14. Antibody based diagnosis of invasive aspergillosis[11] 713 
Population Intention Intervention SoR QoE Comment Ref. 
Any To 
diagnose 
IA 
Aspergillus-specific antibodies by EIA: Serion 
(Germany), Omega (France), Bio-Rad (France), 
Dynamiker (China) 
C II Antibodies take a mean of 11 days to develop 
after onset of illness; detectable in 29% to 
100% of patients during course of acute IA 
[470-477] 
Precipitating antibodies by agar gel double 
diffusion (Microgen Ltd. UK) or counter-
immuno-electrophoresis 
C III 
Consider false-negative results due to 
hypogammaglobulinaemia 
[478] 
Agglutinating antibodies by indirect 
haemagglutination (EliTech/Fumouze, France) 
C II [478] 
Specific immunoglobulins to Aspergillus by 
ImmunoCap® 
C III No 
reference 
found 
SoR, Strength of recommendation; QoE, Quality of evidence; EIA, enzyme immunoassay; IA, invasive aspergillosis 714 
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Table 15. Indications for testing for azole resistance in clinical Aspergillus isolates 715 
Population Intention Intervention SoR QoE Comment Ref. 
All clinically relevant Aspergillus 
isolates (in patient groups or regions 
with known azole resistance) 
Identify azole 
resistance 
Reference MIC testing A II 
In situations where rapid 
testing is available 
[105, 111, 
114, 116, 
300, 479-
489] 
Clinically relevant Aspergillus isolates 
in patient groups with high 
prevalence of azole resistance or 
patients unresponsive to treatment 
Identify isolates with 
intrinsic resistance 
Species identification to 
complex level 
A III 
Some species are 
intrinsically resistant – e.g. 
A. calidoustus (azole 
resistant) and A. terreus 
(AmB resistant) 
[103, 490] 
Clinically relevant A. fumigatus 
isolates 
Identify azole 
resistant A. fumigatus 
Routine azole agar 
screening 
B III 
Identifies resistant colonies 
that require MIC-testing 
[118, 491] 
All isolates –resistance surveillance 
Determine the local 
epidemiology of azole 
resistance 
Periodical reference MIC 
testing of A. fumigatus 
complex 
A II Test at least 100 isolates 
[105, 111, 
114, 300, 
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482-485, 
487-489] 
Azole-resistant isolates 
Determine nature 
and trends in Cyp51A 
mutation distribution 
Cyp51A-gene mutation 
analysis 
A II 
Test resistant isolates from 
surveillance survey 
[107] 
SoR, Strength of recommendation; QoE, Quality of evidence; AmB, Amphotericin B; MIC, minimum inhibitory concentration  716 
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Table 16. Azole susceptibility testing: Timing, methods, and number colonies 717 
Population Intention Intervention SoR QoE Comment Ref. 
Any 
Confirm or reject azole 
resistance in clinical A. 
fumigatus isolates when 
antifungal treatment is 
considered 
Azole agar screening test 
followed by reference MIC 
test where needed 
A III 
MIC testing as soon as the strain is 
isolated and without waiting for species 
ID 
[103, 114] 
Detect azole-resistant A. 
fumigatus genotypes in a 
single culture 
Reference MIC testing of 
multiple colonies 
(up to 5 colonies) 
B III 
Multiple genotypes, i.e. azole-
susceptible and azole-resistant, may be 
present 
[115, 492, 
493] 
Routine azole agar screening 
(up to 5 colonies) 
B III 
One resistant colony can be identified 
among 4 susceptible samples together 
as recently validated. 
[118, 491] 
Confirm or reject azole 
resistance by a validated 
method 
MIC test using EUCAST 
method and EUCAST BPs (S, I, 
R) 
A III 
Applicable to all Aspergillus spp. 
Breakpoints established for most 
species 
[494-496] 
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 MIC test using CLSI method 
and CLSI ECVs (wild-
type/non-wild-type)  
B III Breakpoints not established [496] 
MIC testing of various 
Aspergillus spp. 
Etest® C III 
Confirmation by reference test 
recommended. 
[497-501] 
SoR, Strength of recommendation; QoE, Quality of evidence; MIC, minimum inhibitory concentration  718 
 56 
Table 17. Azole MIC testing: Choice of azole compounds 719 
Population Intention Intervention SoR QoE Comment Ref. 
Any To determine susceptibility to 
itraconazole 
MIC (EUCAST/CLSI) A III In general, a sensitive marker for azole 
resistance in Aspergillus; test itraconazole and 
voriconazole as a minimum 
[495, 496, 
502-506] 
Any To determine susceptibility to 
voriconazole 
MIC (EUCAST/CLSI) A III Resistance/reduced susceptibility to other 
azole(s) may accompany that of voriconazole; 
isolated voriconazole resistance described 
related to TR46 mutation 
[114, 494, 
496, 504-507] 
Any To determine susceptibility to 
posaconazole 
MIC (EUCAST/CLSI) B III Posaconazole resistance without itraconazole 
resistance not reported so far; current EUCAST 
breakpoint will misclassify approximately 15% 
susceptible isolates as I/R 
[300, 486, 
495, 496, 
504-509] 
Any To determine susceptibility to 
isavuconazole 
MIC (EUCAST/CLSI) A III MIC often similar to voriconazole, but needs 
testing separately, if isavuconazole is to be 
used; lower MIC of isavuconazole as compared 
[495, 504, 
505, 507, 
510-512] 
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to itraconazole and voriconazole for A. lentulus 
and A. udagawae (A. fumigatus complex) 
(CLSI) 
SoR, Strength of recommendation; QoE, Quality of evidence; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial 720 
Susceptibility Testing; CLSI, Clinical & Laboratory Standards Institute 721 
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Table 18. Amphotericin B susceptibility testing 723 
Population Intention Intervention SoR QoE Comment Ref. 
Clinically 
relevant 
isolate 
Confirm or reject AmB 
resistance when 
antifungal treatment is 
considered 
MIC test C III Acquired resistance to amphotericin B is very rare and 
therefore correlation with clinical outcome has not been 
documented apart from the poorer outcome for high MIC 
species (A. terreus and A. flavus compared to A. fumigatus). 
[513-516] 
Clinically 
relevant 
isolate 
Interpretation of MIC 
(EUCAST) 
MIC test using 
EUCAST method and 
EUCAST break points 
(S, I, R) 
B III MIC break points proposed for A. fumigatus and A. niger [495, 517, 
518] Epidemiologic cut-offs established for A. flavus, A. fumigatus, 
A. niger and A. terreus 
A. terreus is not considered a good target for AmB. A. flavus 
may be in vitro resistant 
Clinically 
relevant 
isolate 
Interpretation of MIC 
(CLSI) 
MIC test using CLSI 
method and CLSI 
ECVs (wild-type/non-
wild-type) 
B III ECVs proposed for A. fumigatus, A. flavus, A. nidulans, A. 
niger, A. terreus, A. versicolor. No clinical break points. A. 
terreus and flavus, e.g. with MIC below the ECV are not good 
targets for AmB. No clinical data that A. fumigatus with MIC 2 
[519] 
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will respond to AmB although classified as wildtype according 
to CLSI ECVs. 
SoR, Strength of recommendation; QoE, Quality of evidence; AmB, amphotericin B; CLSI, Clinical & Laboratory Standards Institute; ECV, epidemiological cut-724 
off value; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration 725 
  726 
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Table 19. Antifungal regimens in intrinsic resistance 727 
Population Intention Intervention SoR QoE Comment Ref. 
AŵphoteriĐiŶ B MIC шϭ 
mg/L 
To cure IA Replace AmB with azole, if azole tested 
susceptible 
B II 
 
[17, 170, 520-
525] 
IA due to A. terreus To cure IA Voriconazole A II Avoid AmB [162, 526, 
527] Isavuconazole A II 
Posaconazole B III 
Itraconazole B III 
IA due to A. calidoustus To cure IA Lipid formulation of AmB A II Avoid azoles [103, 528] 
IA due to A. tubingensis 
(A. niger complex) 
To cure IA Other than azole monotherapy C III Higher azole MIC common, but no data 
on clinical impact 
[501, 529, 
530] 
IA due to A. lentulus (A. 
fumigatus complex) 
To cure IA Other than azole monotherapy 
IA due to A. alliaceus (A. 
flavus complex) 
To cure IA Other than AmB monotherapy C III Avoid AmB [531] 
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IA due to A. niger 
complex 
To cure IA Other than itraconazole and isavuconazole B III Isavuconazole, posaconazole, and 
voriconazole MIC in general 1 dilution 
higher compared to A. fumigatus; 
itraconazole MIC in general 2 steps 
higher; limited clinical data 
[501, 512] 
IA due to A. nidulans To cure IA Voriconazole C III AmB MIC elevated, poor clinical 
responses in chronic granulomatous 
disease 
[532, 533] 
SoR, Strength of recommendation; QoE, Quality of evidence; AmB, amphotericin B; IA, invasive aspergillosis; MIC, minimum inhibitory concentration 728 
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Table 20. Optimal therapy in documented azole-resistance 729 
Population Intention Intervention SoR QoE Comment Ref. 
Isolate with 
voriconazole MIC =2 
mg/ml 
To cure IA Voriconazole + echinocandin 
combination therapy or L-AmB 
monotherapy for IA (as well as 
for CPA) 
A III The probability of voriconazole treatment 
failure may be higher than in voriconazole MIC 
<2. 
[534-536] 
Isolate with 
posaconazole MIC 
>0.5 mg/ml [537] 
To cure IA L-AmB A IIu 
 
[113, 114, 
538] 
AmB lipid complex C III 
 
No reference 
found. 
Voriconazole & anidulafungin B III 
 
[534] 
Posaconazole & caspofungin C III Posaconazole not licensed for primary 
treatment 
[539] 
Caspofungin or micafungin C III Patients with contra-indications to AmB & 
other azoles 
No reference 
found. 
SoR, Strength of recommendation; QoE, Quality of evidence; AmB, Amphotericin B; CPA, chronic pulmonary aspergillosis; IA, invasive aspergillosis; L-AmB, 730 
Liposomal amphotericin B; MIC, minimum inhibitory concentration  731 
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Table 21. Therapeutic drug monitoring 732 
Clinical scenarios where antifungal 
therapeutic drug monitoring may be 
indicated 
Examples, comments 
Populations with increased 
pharmacokinetic variability 
Impaired gastrointestinal function; hepatic dysfunction; children, elderly patients, obese patients, critically-ill 
patients 
Changing pharmacokinetics 
Intravenous to oral switch, changing gastrointestinal function, changing hepatic or function, physiological-
instability 
Interacting medications 
Patient receiving medication known to induce cytochrome P450 enzymes especially CYP3A4, antacids, 
proton-pump inhibitors (itraconazole capsules, posaconazole suspension), antiretroviral medications. 
Patients should have medication records screened using drug interactions screening database before starting 
and stopping antifungals (example: www.fungalpharmacology.org, fungal-druginteractions.org, or 
http://www.aspergillus.org.uk/content/antifungal-drug-interactions) 
Poor prognosis disease 
Extensive or bulky infection, lesions contiguous with critical structures, CNS infection, multifocal or 
disseminated infection 
Compliance concerns Important issue with longer-term consolidation therapy or secondary prophylaxis in outpatient setting 
 64 
Suspected breakthrough infection 
TDM can establish whether fungal disease progression occurred in the setting of adequate antifungal 
exposure 
Suspected drug toxicity, especially 
neurotoxicity (voriconazole) 
Exposure-response relationships are described for other toxicities (e.g., hepatotoxicity), the utility of TDM to 
prevent their occurrence is less well established 
CNS, central nervous system; TDM, therapeutic drug monitoring 733 
  734 
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Table 22. Itraconazole therapeutic drug monitoring 735 
Population Intention Intervention SoR QoE Comment Ref. 
All patients receiving 
itraconazoletreatment 
for IA 
Improve efficacy 
Measure serum trough 
level on day 5 of 
therapy or soon after 
A II 
Target itraconazole level >1 mg/L to 4 mg/L by HPLC. 
Hydroxy-itraconazole metabolite concentrations generally 
reported separately by HPLC or LC/MS/MS methods, but 
iŶĐluded iŶ ͞itraĐoŶazole͟ ĐoŶĐeŶtratioŶ report ďǇ ďioassaǇ. 
Therapeutic range by bioassay may vary by laboratory but 
typically fall in the range of (3-17 mg/L) 
[122, 127, 
540-542] 
All patients receiving 
itraconazole for 
prophylaxis for IA 
Improve efficacy 
Measure serum trough 
level on day 5 of 
therapy or soon after 
A II 
Target itraconazole level >0.5 mg/L (HPLC) or > 3 mg/L 
(bioassay) 
[124] 
Patients receiving 
itraconazole 
Reduce toxicity 
Measure serum trough 
level on day 5 of 
therapy or soon after 
B II 
Toxicity was associated with itraconazole levels >17.1 mg/L 
by itraconazole bioassay, which correspond to ~4 mg/L by 
HPLC 
[127] 
SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; HPLC, high performance liquid chromatography; LC, liquid 736 
chromatography; MS, mass spectrometry  737 
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Table 23. Voriconazole therapeutic drug monitoring 738 
Population Intention Intervention SoR QoE Comment Ref. 
All patients 
receiving 
voriconazole 
treatment for IA 
Improve efficacy, 
safety and 
compliance 
Measure plasma trough level 
after 2-5 days of therapy or 
soon after 
A II Target range of 1-5.5 mg/L [128-131, 
133, 543-
545] 
Repeat plasma trough level B II Repeat during second week of therapy, additional 
samples as clinically indicated and outlined in the 
text 
[128-131, 
133, 543-
545] 
All patients 
receiving 
voriconazole 
prophylaxis for IA 
Improve efficacy, 
safety and 
compliance of 
prophylaxis 
Measure serum trough level 
after 2-5 days of therapy or 
soon after, and 4 days after 
change of dose 
A IIt As above; most studies investigated voriconazole 
treatment rather than prophylaxis 
[132, 546, 
547] 
Patients with IA due 
to Aspergillus strains 
of reduced azole 
Improve efficacy of 
treatment for 
isolates with MIC=2 
mg/ml 
Measure serum trough level 
after 2 to 5 days of therapy 
or soon after and 4 days after 
change of dose 
A II Trough >2 mg/L recommended on the basis of 
PK/PD analysis 
[131, 548] 
 67 
susceptibility MIC =2 
mg/ml 
SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; MIC, minimum inhibitory concentration; PK, pharmacokinetic; PD, 739 
pharmacodynamic  740 
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Table 24. Posaconazole therapeutic drug monitoring 741 
Population Intention Intervention SoR QoE Comments Ref. 
Patients 
receiving 
posaconazole 
suspension for 
treatment of 
IA 
Improve 
efficacy, 
compliance 
Serum trough level on day 5 of therapy or 
soon after 
A II Target level >1 mg/L. 
Gastroresistant tablet or intravenous formulation 
preferred for most patients, consider switch to 
tablet or IV, if no therapeutic levels with oral 
suspension 
Repeat determination as clinically appropriate 
Longed half-life gives similar results for random 
sampling and true trough samples 
[138] 
Patients 
receiving 
posaconazole 
suspension for 
prophylaxis to 
prevent IA 
Improve 
efficacy, 
compliance 
Serum trough level on day 5 of therapy or 
soon after. 
C II Target level >0.7 mg/L 
Adequate tissue concentrations may occur despite 
serum concentration <0.7 mg/L 
Repeat determination as clinically appropriate 
[136, 137, 
549-552] 
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Patients 
receiving 
posaconazole 
Improve 
safety 
Measure serum trough level on day 5 of 
therapy or soon after 
C III If treatment failure or toxicity suspected, TDM may 
be indicated in patients receiving gastroresistant 
tablet or intravenous formulation 
Posaconazole exposures between 0.5-3.75 mg/L are 
well studied and considered safe and effective with 
all three formulations 
Posaconazole plasma levels above this exposure 
range may be associated with toxicity 
[120,121] 
SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; IV, intravenous; TDM, therapeutic drug monitoring; AML, acute 742 
myeloid leukaemia; HSCT, haematopoietic stem cell transplantation; GvHD, graft versus host disease 743 
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Table 25. Isavuconazole therapeutic drug monitoring 745 
Population Intention Intervention SoR QoE Comment Ref. 
All patients 
receiving 
isavuconazole 
Improve efficacy 
safety and 
compliance 
Measure serum trough level on 
D5 of therapy or soon after 
C III 
Limited data to support routine TDM but may 
be indicated in the setting of treatment 
failure, drug interactions, or if toxicity is 
suspected 
The long half-life of isavuconazole (130 hours) 
may support use for TDM in some clinical 
situations to confirm drug clearance prior to 
starting medications metabolized by CYP3A4, 
especially chemotherapy agents 
FDA advisory 
briefing 
documents 
SoR, Strength of recommendation; QoE, Quality of evidence; TDM, therapeutic drug monitoring; FDA, Food and Drug Administration  746 
 71 
Table 26. Primary prophylaxis 747 
Population Intention Intervention SoR QoE Comment Ref 
Haematological malignancies, 
e.g. AML with prolonged and 
profound neutropenia 
Lower 
incidence of IA 
Posaconazole 200 mg tid suspension 
or 300 mg tablet qd 
A I AML/MDS induction only. TDM 
especially with oral suspension. 
Tablets more bioavailable, bridging 
with posaconazole IV formulation 
possible 
[553] 
L-AmB 12.5 mg biw, nebulized, with 
undetermined dose of fluconazole 
B I AML [554, 555] 
ABLC 3 mg/kg 3x/weekly C IIh No difference to L-AmB regimen [556] 
Micafungin 50 mg qd C IIt 
 
[560, 561] 
L-AmB 10 mg/kg q7d C IIu 
 
[562] 
L-AmB 50 mg abs q2d C IIu 
 
[563] 
L-AmB 15 mg/kg q14d C IIu 
 
[564] 
Voriconazole C IIt Not better than fluconazole [565] 
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Itraconazole 400 mg/d, oral solution D II No difference to fluconazole (n=195) 
and more toxicity 
[121, 557-
559] 
Acute lymphoblastic 
leukaemia, remission 
induction chemotherapy 
Lower 
incidence of IA 
L-AmB 5 mg/kg biw D I L-AmB more toxic than placebo, no 
significant reduction in IA rate 
[566] 
Autologous HSCT or 
treatment of haematological 
malignancies besides acute 
leukaemia 
Lower 
incidence of IA 
Any mould active agent D III  
No 
reference 
found. 
Allogeneic HSCT (until 
neutrophil recovery) 
Lower 
incidence of IA 
Posaconazole 200 mg tid suspension 
or 300 mg tablet qd 
B IIt Neutropenia duration approximately 
identical, TDM* 
[553] 
L-AmB 12.5 mg biw, nebulized, with 
fluconazole 
B IIt  [554] 
Voriconazole 200 mg bid C I Not better than fluconazole, TDM [567, 568] 
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Micafungin 50 mg/d C I But no difference in subgroup 
analysis for aspergillosis 
[560] 
Itraconazole 400 mg/d oral solution D I Toxicity issues; TDM [554, 559] 
Allogeneic HSCT (after 
neutrophil recovery and no 
GvHD) 
Any antifungal agent D III No study demonstrated outcome 
advantage 
 
Allogeneic HSCT (with 
moderate to severe GvHD 
and/or intensified immuno-
suppression) 
Posaconazole 200 mg tid suspension 
or 300 mg tablet qd 
A I TDM [569] 
Voriconazole 200 mg bid C II Not better than fluconazole; TDM [567, 568] 
Itraconazole 400 mg/d, oral solution C II Toxicity issues; TDM [559] 
Micafungin 50 mg/d C III Only few patients with GVHD [560] 
Allogeneic HSCT (until 
neutrophil recovery) To reduce IA 
attributable 
mortality 
Posaconazole 200 mg tid suspension 
or 300 mg tablet qd 
B IIt Neutropenia duration approximately 
identical. TDM 
[553] 
Allogeneic HSCT (after 
neutrophil recovery, without 
GvHD) 
Any other antifungal D III No study demonstrated outcome 
advantage 
 
 74 
Allogeneic HSCT (with 
moderate to severe GvHD 
and/or intensified immuno-
suppression) 
Posaconazole 200 mg tid suspension 
or 300 mg tablet qd 
A II Mainly IFD-attributable mortality, 
TDM 
[569] 
SoR, Strength of recommendation; QoE, Quality of evidence; qd, once daily; bid, twice daily; tid, thrice daily; AML, acute myeloid leukaemia; MDS, 748 
myelodysplastic syndrome; TDM, therapeutic drug monitoring; ABLC, amphotericin B lipid complex; L-AmB, Liposomal amphotericin B; HSCT, 749 
haematopoietic stem cell transplantation; GvHD, graft versus host disease; IFD, invasive fungal disease 750 
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Table 27. Targeted therapy of pulmonary disease – First line 752 
Population Intention Intervention SoR QoE1 QoE2 QoE3 Comment Ref. 
1 Neutropenia 
(non- allo 
HSCT 
recipients) 
 
2 Allo-HSCT 
(during 
neutropenia) 
 
3 Allo-HSCT 
(w/o 
neutropenia) 
or other non-
To increase 
response and 
survival rate 
Isavuconazole 200 mg iv tid day 1-2, then 
200 mg qd oral 
A I IIt IIt 
D III, if mould active azole 
prophylaxis 
less adverse effects than 
voriconazole 
[173, 512, 
633, 634] 
Voriconazole 2x 6 mg/kg IV (oral 400 mg bid) 
on day 1, then 2x 4 mg/kg IV (oral 200 to 300 
mg bid) 
A I IIt IIt 
C III for start with oral;  
D III, if prior mould active 
azole prophylaxis; TDM 
[170, 172, 
512, 635] 
L-AmB 3 mg/kg B II IIt IIt 
 
[171] 
Combination of voriconazole 6/4 mg/kg bid 
(after one week oral possible (300 mg bid)) + 
anidulafungin 200/100 mg 
C I IIt, IIt, 
No significant difference 
compared to voriconazole, 
in GM positive (subgroup) 
better survival; TDM 
[172, 635] 
Caspofungin 70 mg qd day 1, followed by 50 
mg qd (if body weight <80kg) 
C II II II 
 
[618-620] 
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neutropenic 
patients Itraconazole 200 mg q12h iv on day 1, then 
200 mg/qd 
C III IIt,a IIt,a 
D III for start with oral, 
TDM 
D III, if mould active azole 
prophylaxis 
[512, 542] 
AmB lipid complex (ABLC) 5 mg/kg C III III III  [636] 
Micafungin 100 mg C III III III 
 
[637-639] 
AmB colloidal dispersion (ABCD) 4-6 mg/kg D I IIt IIt  [142] 
Conventional AmB 1-1.5 mg/kg D I IIt IIt 
 
[170] 
Other combinations D III III III Efficacy unproven [640] 
Life-
threatening 
haemoptysis 
Bridging until 
neutrophil 
recovery 
Arterial embolization, emergency surgical 
intervention 
B III III III  [641] 
SoR, Strength of recommendation; QoE, Quality of evidence; allo-HSCT, allogeneic haematopoietic stem cell transplantation; bid, twice daily; tid, thrice 753 
daily, qd, once daily; IA, invasive aspergillosis; IV, intravenous; TDM, therapeutic drug monitoring; GM, galactomannan   754 
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Table 28. Targeted therapy of extrapulmonary disease – First line 755 
Population Intention Intervention SoR QoE Comment Ref 
Suspected or proven IA of 
the central nervous 
system 
To increase 
response and 
survival rate 
Surgical debridement, if 
surgically possible 
A IIu 
 
[642, 
643] 
Voriconazole A IIu 
N=5/5 [170] 
N=81, 48 proven cases, 33 probable cases, TDM 
recommended targeting trough concentration of 2-5.5 
mg/L 
[642] 
Posaconazole D III 8 patients documented in studies (5 failures) [644] 
Itraconazole D III  
 
Lipid formulations of AmB B III Case collections, animal data 
[645-
647] 
cAmB D I Renal toxicity 
[189, 
648-
650] 
Echinocandins D III Insufficient tissue penetration [646] 
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Patients with clinical 
suspicion of or proven 
invasive sinus aspergillosis 
To cure 
Surgery A III Need to be considered on an individual basis and decision 
 
Local antifungal therapy C III 
  
Patients with invasive 
sinus aspergillosis (all 
levels of certainty: 
suspected through 
proven) 
Voriconazole A IIt N=8/7, TDM recommended 
[170, 
651] 
L-AmB A IIt 
Active against mucormycosis as well since mixed 
infections occur or cannot be differentiated 
[171] 
Posaconazole, itraconazole, 
echinocandins 
C III 
Not well specified in studies, TDM recommended for 
posaconazole and itraconazole 
[652, 
653] 
SoR, Strength of recommendation; QoE, Quality of evidence; TDM, therapeutic drug monitoring; AmB, Amphotericin B, cAmB, conventional amphotericin B; 756 
L-AmB, liposomal amphotericin B 757 
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Table 29. Fever-driven (͞eŵpiriĐ͟) approach 759 
Population Intention Intervention SoR QoE Comment Ref 
Chemotherapy for 
haematological 
malignancies or HSCT, 
ŶeutropeŶia <ϱϬϬ/µL ш 96 
h, fever (>38°C), and 
parenteral broad 
spectrum antibacterial 
therapǇ ш 96 h (some 
centres consider 48h) 
Reduction in the 
incidence of IA 
and/or related 
mortality 
Caspofungin 70 mg qd day 1, 
followed by 50 mg qd (if body 
weight <80kg) 
A I 
Caspofungin was associated with a significantly 
higher rate of survival than L-AmB (subgroup 
analysis). 
[188] 
L-AmB 3 mg/kg B I 
Less toxicity in comparison to cAmB but more renal 
toxicity compared to echinocandin 
[188, 
189] 
Voriconazole 6 mg/kg bid IV 
(oral 400 mg bid) on day 1, 
then 4 mg/kg bid IV (oral 200 to 
300 mg bid) 
B II 
Failed the 10% non-inferiority cut-off when 
compared with L-AmB, but first-line for aspergillosis. 
Activity of azoles empirical therapy for persistent 
fever may be limited in patients receiving 
prophylaxis with an agent of the same class. TDM* 
[190] 
Itraconazole 200 mg qd iv C II 
Activity of azoles empirical therapy for persistent 
fever may be limited in patients receiving 
prophylaxis with an agent of the same class. TDM* 
[666] 
ABLC 5 mg/kg qd C I Infusion-related toxicity (fever, chills, hypoxia) [667] 
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ABCD 4 mg/kg C I Same as above [668] 
cAmB 0.5-1 mg/kg qd D I Poor tolerance due to extreme toxicity 
[189, 
342, 
649, 
650, 
666, 
668] 
Micafungin 100 mg qd B II 
 
[669] 
Fluconazole D IIr No activity against Aspergillus [670] 
SoR, Strength of recommendation; QoE, Quality of evidence; L-AmB, liposomal amphotericin B; cAmB, conventional amphotericin B; IV, intravenous; TDM, 760 
therapeutic drug monitoring; ABLC, amphotericin B lipid complex; ABCD, amphotericin B colloidal dispersion  761 
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Table 30. Non-haematological patients at high risk 762 
Population Intention Intervention SoR QoE Ref. 
SOT lung with pre-transplantation colonization and Aspergillus in intraoperative 
culture OR CMV disease OR higher donor age OR prolonged ischaemia time OR 
receiving daclizumab OR bronchial anastomotic ischemia OR bronchial stent OR 
single lung SOT 
To identify patients 
with high risk of IA 
Consider 
prophylaxis 
B III [210, 226, 692] 
[215, 693-695] 
SOT lung with repeated acute and chronic rejection B IIt [696, 697] 
SOT heart with re-operation, CMV infection, haemodialysis, other episode of IA 
in the program within 2 months 
To identify patients 
with high risk of IA 
Consider 
prophylaxis 
A IIh [204] 
SOT heart with airborne Aspergillus spores in ICU A II [203, 204] 
SOT heart with sirolimus OR tacrolimus OR hypogammaglobulinemia B IIh [212, 698] 
SOT liver with one of the following characteristics: requirement for dialysis OR 
retransplantation OR fulminant hepatic failure OR MELD score >30 
To identify patients 
with high risk of IA 
Consider 
prophylaxis 
B IIh [210, 211, 217, 
224, 308, 311, 
607, 699-702] 
 82 
SOT liver with one of the following characteristics: ICU admission or 
corticosteroid requirement previous 2-4 weeks to transplant OR >15 units of 
packed red blood cells during transplant surgery OR reoperation involving the 
intraabdominal cavity OR choledochojejunostomy 
C III 
 
SOT kidney with one of the following characteristics: Pre-transplant COPD OR 
delayed graft function OR post-transplant blood stream infection OR acute graft 
rejection 
To identify patients 
with high risk of IA 
Consider 
prophylaxis 
A IIh [228] 
COPD with one of the following characteristics: high (systemic) cumulative 
glucocorticosteroid dose OR refractory to antibiotic therapy OR admission to the 
intensive-care unit 
To identify patients 
with high risk of IA 
Consider 
prophylaxis 
A IIt [232, 257, 703, 
704] 
HIV with CD4 count <100 cells/µl To identify patients 
with high risk of IA 
Consider 
prophylaxis 
A IIh [232] 
ICU patients with either COPD OR requiring glucocorticosteroids therapy To identify patients 
with high risk of IA 
Consider 
prophylaxis 
A IIh [257, 703, 704] 
ICU patients with either acute liver failure OR burns OR severe bacterial 
infection OR malnutrition 
B III 
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ICU or SOT recipients with Increased environmental exposure To identify patients 
with high risk of IA 
Consider 
prophylaxis 
A II [203, 204, 
705, 706] 
Liver insufficiency To identify patients 
with high risk of IA 
Consider 
prophylaxis 
B IIh [244, 707] 
Burn patients with positive fungal cultures To identify patients 
with high risk of IA 
Consider 
prophylaxis 
A IIh [708, 709] 
Percentage of total body surface area burn injury; length of stay B III [706] 
Patient receiving one of the following: TNF-α ďloĐkers, ďasiliǆiŵaď, daĐlizuŵaď, 
infliximab, etanercept, alemtuzumab, adalimumab, rituximab, abatacept 
To identify 
populations at high 
risk of IA 
Consider 
prophylaxis 
C III No reference 
found. 
SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; CMV, cytomegalovirus; ICU, intensive care unit; COPD, chronic 763 
obstructive pulmonary disease; BAL, bronchoalveolar lavage 764 
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Table 31. Diagnosis-driven ;͞pre-eŵptive͟Ϳ approach in non-haematological patients 766 
Population Intention Intervention SoR QoE Comment Ref. 
COPD To diagnose IA Respiratory culture A IIu Isolation of Aspergillus in culture from admitted patients with COPD 
represents IA in at least 22% of patients 
[257, 281, 
282, 710] 
COPD To diagnose IA GM BAL B IIu Sensitivity/specificity of BAL GM >1.0 cut-off is 67% / 96%, at GM 
>0.5 cut-off is 89% / 88% 
[281] 
Underlying 
respiratory 
disease 
To diagnose IA Lateral flow device BAL C II Sensitivity / specificity 77% / 92% 
(Not commercially available at the time of writing) 
[285] 
HIV To diagnose IA Direct microscopy A IIh 50% positive [232] 
HIV To diagnose IA GM BAL B IIu 53% positive [232] 
HIV To diagnose IA GM serum B IIu 34% positive [232] 
HIV To diagnose IA Histology A IIu 75% positive [232] 
ICU To diagnose IA BDG serum B IIu Autopsy study, non-haematological immunocompromised critically [429] 
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ill patients with lower respiratory tract infection. Using 140 pg/ml 
cut-off, sensitivity/specificity 100% / 70% 
ICU To diagnose IA BDG serum B IIu BDG appeared a mean of 6.5 days before Aspergillus was grown [711] 
ICU To diagnose IA Respiratory culture B IIu  [89, 712, 
713] 
ICU To diagnose IA GM BAL C IIu Using cut-off ODI 0.5 sensitivity/specificity 88-90% / 87-100% [89, 712, 
713] 
ICU To diagnose IA SeptiFast® C IIh Sensitivity/specificity 66% / 98%, PPV 93%, NPV 88% [714, 715] 
Non 
haematological 
To diagnose IA Culture A IIh Very low PPV of Aspergillus spp. culture from respiratory samples [197] 
Non 
haematological 
To diagnose IA Culture A IIh Sensitivity of BAL higher for non-neutropenic patients [52] 
Non-
haematological 
To diagnose IA GM serum C II Using cut-off of 0.5 ng/ml sensitivity/specificity 60% / 89% [710] 
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Non-
haematological 
To diagnose IA MycAssay Aspergillus® C II Sensitivity, specificity, PPV, and NPV of first sample/any sample were 
87%/93%, 87%/82%, 34%/34%, 92%/100% 
[278] 
SOT, any To diagnose IA Respiratory culture D II Low sensitivity and specificity [87, 282] 
SOT, any To diagnose IA GM BAL B II Using cut-off ODI 1.0 sensitivity/specificity 100% / 91% [716] 
SOT, any To diagnose IA High-resolution chest 
computed tomography 
A III Bilateral bronchial wall thickening and centrilobular opacities, tree-
in-bud pattern (65%), ground-glass opacities and/or bilateral areas 
of consolidation (23%) 
[214, 717] 
SOT, any To diagnose IA Lateral flow device BAL C II N=11 SOT [284, 434, 
718] 
SOT Heart To diagnose IA Respiratory culture A IIh Overall positive predictive value (PPV) 60-70%, PPV 88-100% with 
respiratory specimens other than sputum; recovery of A. fumigatus 
PPV 78-91% 
[271] 
SOT Heart To diagnose IA High-resolution 
computed tomography 
A IIh Provided significant additional information in 41%; positive with a 
normal chest X-ray in 18% 
[274] 
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of the thorax 
SOT Lung To diagnose IA BDG serum C IIu Sensitivity/specificity 64%, 9%, PPV 14%, NPV 50% [719] 
SOT Lung To diagnose IA GM BAL B II Using cut-off ODI 1.5 sensitivity/specificity 100% / 90% [87, 88, 
720, 721] 
SOT Lung To diagnose IA PCR of respiratory 
samples 
B II  [88] 
SoR, Strength of recommendation; QoE, Quality of evidence; COPD, chronic obstructive pulmonary disease; BDG, ß-D-glucan; IA, invasive aspergillosis; ICU, 767 
intensive care unit; SOT, solid organ transplantation; PPV, positive predictive value; GM, galactomannan; ODI, optical density index; NPV, negative predictive 768 
value; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction  769 
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Table 32. Treatment in non-haematological patients 770 
Population Intention Intervention SoR QoE Comment Ref. 
HIV To treat IA Voriconazole A III Consider drug-drug interactions with antiretroviral drugs. [722] 
SOT Heart To treat IA Itraconazole C III 6 patients cured with itraconazole 200-400 mg/d 
Erratic absorption and interaction with calcineurin inhibitors and other 
agents 
[723] 
SOT, any To treat IA Voriconazole A III e.g. Herbrecht study 11 SOT; voriconazole increases the levels of anti-
calcineurin immunesuppressors, TDM; monitor liver function tests 
especially in liver transplant recipients. 
[170, 214, 
287, 333, 
607-609, 
673, 724-
726] 
SOT, any To treat IA L-AmB A II 
 
[678, 727, 
728] 
SOT, any To treat IA Voriconazole & B II 40 SOT voriconazole & caspofungin (n=40) vs amphotericin B (n=47). [289] 
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caspofungin Survival benefit in pts with A. fumigatus or renal insufficiency 
SOT, if 
voriconazole 
contraindicated 
To treat IA Caspofungin B III Complete response 83%; response 7/9 monotherapy and 7/10 
combination 
[621, 622, 
686, 729] 
SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; SOT, solid organ transplantation; L-AmB, Liposomal amphotericin B; SOT, 771 
solid organ transplantation; TDM, therapeutic drug monitoring 772 
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Table 33. Prophylaxis in non-haematological patients 774 
Population Intervention Intention SoR QoE Comment Reference 
SOT Lung Universal* prophylaxis To prevent IA A I Invasive fungal infection appeared at a median of 35 days [304, 315, 
730] 
Targeted* prophylaxis To prevent IA C III  [315, 694, 
731] 
Inhaled cAmB To prevent IA B IIh 25 mg/day for 4 days, followed by 25 mg/week for 7 weeks. More 
adverse events in inhaled deoxycholate vs lipid-based 
Breakthrough IA in 7-10% 
[732, 733] 
Inhaled lipid-based 
AmB 
To prevent IA A I More adverse events with inhaled deoxycholate vs lipid-based but 
similar efficacy; various possible protocols: 50mg/day for 4 days, then 
50mg/week for 7 weeks; 50mg/day for 2 weeks, then once weekly for 
10 weeks; 25mg thrice weekly between day 1 and day 60 post SOT 
and once weekly between day 60 and day 180 
[724, 732-
735] 
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Voriconazole To prevent IA A III Voriconazole 2x200 mg/d more hepatotoxic than itraconazole 2x200 
mg/d. Usual duration of prophylaxis 3-6 months; monitor liver and 
skin toxicity 
[303, 304, 
315, 731, 
736] 
Voriconazole pre-
emptive, if colonized 
To prevent IA B IIu Breakthrough IA <2% at 6 months [731] 
Voriconazole for three 
months 
To prevent IA C II No effect of voriconazole on the incidence of IA (45% vs 49%) [303] 
SOT Heart Universal* prophylaxis 
with itraconazole or 
inhaled AmB 
To prevent IA C I 
 
[214, 737, 
738] 
Universal* prophylaxis 
with itraconazole or 
inhaled AmB 
To prevent IA C II IA rates 5% without prophylaxis, 1.5% with itraconazole 2x200 mg, 
0% with inhaled AmB 
[214, 737, 
738] 
Targeted* prophylaxis 
with echinocandins 
To prevent IA A IIt Prophylaxis in 10% of patients, IA rate reduced from 9% to 2%, 
attributable mortality from 6% to 2%; duration dependant of risk 
[215] 
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factors persistence 
SOT Liver Targeted* prophylaxis 
with lipid AmB 
To prevent IA B III IA rate reduced, mortality unaffected [607, 739-
741] 
Targeted* prophylaxis 
with echinocandins 
To prevent IA A I Standard dosed echinocandins reduced IA rate; duration of 
prophylaxis usually 21 days post SOT 
[217, 308, 
311, 742] 
SoR, Strength of recommendation; QoE, Quality of evidence; * targeted prophylaxis = only if additional risk factors; universal prophylaxis = to all patients in 775 
population; IA, invasive aspergillosis; SOT, solid organ transplantation; AmB, Amphotericin B; cAmB, conventional amphotericin B deoxycholate 776 
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Table 34. Prophylaxis in children at high risk 778 
Population Intention Intervention SoR QoE Comment Ref 
Allogeneic HSCT, pre-
engraftment phase; 
Allogeneic HSCT, post-
engraftment phase, GvHD 
and augmented 
immunosuppression; 
High-risk patients with de 
novo or recurrent 
leukaemia, bone marrow 
failure syndromes with 
prolonged and profound 
neutropenia 
Prevention of 
IA 
Itraconazole A/B* IIt 
TDM recommended; Approved indication; not approved 
EU < 18 years 
[122, 559, 
570-579] 
Posaconazole A IIt 
TDM recommended; only supportive paediatric data for 
ш ϭϯ Ǉears of age 
[136, 137, 
338, 553, 
569, 580-
586] 
Voriconazole A IIt 
Not approved for <2 years; Inference from efficacy from 
HSCT trials and supportive studies; TDM recommended 
[130, 131, 
135, 546, 
567, 568, 
587-593] 
Liposomal 
amphotericin B 
B IIt/III* 
Not approved for prophylaxis; Optimal dose of alternate 
administration unknown; Alternative if triazoles are not 
tolerated / contraindicated 
[563, 594-
599] 
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Micafungin B IIt/III* 
No definite evidence (trend only) for prophylactic 
efficacy against Aspergillus spp. Alternative if triazoles 
are not tolerated or contraindicated 
[560, 600-
604] 
Chronic granulomatous 
disease (CGD) patients 
Prevention of 
IA 
Itraconazole A II 
Approved indication; not approved in the EU for < 18 
years; TDM recommended 
[122, 575-
578, 605, 
606] 
Posaconazole A III 
Not EU approved for children < 18 years; 
TDM reĐoŵŵeŶded; PK aŶd safetǇ data for ĐhildreŶ ш ϰ 
years 
[136, 137, 
582-585] 
* SoR = B for allogeneic HSCT post-engraftment phase, GvHD (graft versus host disease) and augmented immunosuppression 779 
* QoE = III for allogeneic HSCT post-engraftment phase, GvHD and augmented immunosuppression 780 
SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; TDM, therapeutic drug monitoring; HSCT, haematopoietic stem cell 781 
transplantation 782 
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Table 35. Treatment in children 784 
Population Intention Intervention SoR QoE Comment Ref 
Any paediatric 
population other than 
neonates 
Treatment 
proven/probable IA 
Voriconazole 18 mg/kg/d iv day 1, 
followed by 16 mg/kg/d iv or 18 
mg/kg/d po in 2 divided dosages 
(up to 14 years and < 50 kg); if 
>15 yrs or >12 yrs and >50 kg use 
adult dosing recommendations 
A IIt Not approved in patients <2 yrs; TDM 
recommended. 
[130, 131, 
135, 170, 
333, 546, 
589-592, 
607-613] 
Any paediatric 
population other than 
neonates 
Treatment 
proven/probable IA 
L-AmB 3 mg/kg/d B IIt Comparison between 2 dosages of L-AmB, no 
comparison to voriconazole 
[171, 597, 
599, 614-
617] 
Any paediatric 
population other than 
neonates 
Treatment 
proven/probable IA 
Caspofungin 70 mg/m2 day 1, 
followed by 50 mg/m2/d (max. 70 
mg/d) 
C IIt Study prematurely stopped due to low accrual  [616, 618-
628] 
Neonates Treatment 
proven/probable IA 
L-AmB 3 mg/kg/d A III 
 
[629-632] 
SoR, Strength of recommendation; QoE, Quality of evidence; IA, invasive aspergillosis; TDM, therapeutic drug monitoring; L-AmB, liposomal amphotericin B 785 
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Table 36. Secondary prophylaxis 786 
Population Intention Intervention SoR QoE Comment Ref. 
Previous IA and 
undergoing allogeneic 
HSCT or entering risk 
period with non-
resectable foci of 
Aspergillus disease 
To reduce risk of 
IA recurrence 
Secondary prophylaxis with an Aspergillus 
active antifungal proven to be effective in 
the actual patient 
A II Results compared to historical data, mostly in 
allogeneic HSCT setting 
[654-
659] 
Voriconazole A IIh IA: 31/45 pts, 1 year cumulative incidence of IFD 
6.7±3.6%, TDM 
[654] 
Caspofungin 70 mg day 1, followed by 50 
mg/d IV until stable engraftment, followed 
by 400 mg itraconazole suspension PO 
B IIh 
 
[658] 
L-AmB followed by voriconazole C II Fungal infection related mortality 28% despite 
lipid-based AmB 
[657, 
660] 
Previous IA and with 
resectable foci of 
Aspergillus disease 
To reduce risk of 
IA recurrence 
Surgical resection following by secondary 
prophylaxis 
B III Timing and methods of surgery important. 
Concomitant administration of appropriate 
antifungal compound justified. 
[661-
665] 
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before entering risk 
period 
Indication for surgical intervention by appropriate 
specialist. Interdisciplinary consensus needed. 
SoR, Strength of recommendation; QoE, Quality of evidence; HSCT, haematopoietic stem cell transplantation; IA, invasive aspergillosis, IFD, invasive fungal 787 
disease; TDM, therapeutic drug monitoring, PO, per os; L-AmB, liposomal amphotericin B  788 
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Table 37. Antifungal drugs in refractory disease 789 
Population Intention Intervention SoR QoE Comment Ref 
Haematological 
patients with 
refractory IA 
Achieve complete or 
partial response, or 
stable disease, 
improve survival 
Switch to another drug class A III 
  
Any combination C III No prospective study demonstrated 
superiority of combination therapy 
over monotherapy 
[671] 
Voriconazole A II  
[333, 672-
674] 
L-AmB 3-5 mg/kg  B II Majority voted for BII others for AII 
[598, 675, 
676] 
ABLC 5 mg/kg  C II  
[636, 676-
678] 
ABCD   No longer commercially available [679, 680] 
Caspofungin 70 mg qd day 1, followed by 50 
mg qd (if body weight <80kg) 
B II 
Very few data in case of 
voriconazole/posaconazole failure 
[335, 674, 
681-687] 
Micafungin 75-200 mg qd C II  [638, 688] 
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Posaconazole 200 mg qid or 400 bid 
suspension or 300 mg tablet bid day 1, 
followed by 300 mg qd 
B II  
[138, 336, 
689, 690] 
Itraconazole D III 
In case of refractoriness to 
voriconazole 
 
Itraconazole oral forms C II Poor bioavailability [126] 
Itraconazole IV formulation 
  Commercially not available 
everywhere 
[542, 691] 
SoR, Strength of recommendation; QoE, Quality of evidence; L-AmB, Liposomal amphotericin B; ABLC, amphotericin B lipid complex; ABCD, amphotericin B 790 
colloidal dispersion; IV, intravenous; TDM, therapeutic drug monitoring; qd, once daily; bid, twice daily; qid, four times daily 791 
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Table 38. Chronic pulmonary aspergillosis 793 
Population Intention Intervention SoR QoE Comment Ref.  
Cavitary or nodular 
pulmonary infiltrate in non-
immuno-compromised 
patients 
Diagnosis or exclusion of CPA Direct microscopy for 
hyphae 
A IIt Positive microscopy is a strong indicator of 
infection, not studied in CPA, but in ABPA 
[743] 
Histology A II In CPA histology distinguishes between 
CNPA and CCPA 
[744] 
Fungal culture (respiratory 
secretion) 
A III Bacterial culture plates are less sensitive 
than fungal culture plates 
[269] 
Cavitary or nodular 
pulmonary infiltrate in non-
immuno-compromised 
patients 
Diagnosis or exclusion of CPA Aspergillus IgG antibodies A II IgG and precipitins test standardization 
incomplete 
[364] 
CPA patients with progressive 
disease 
Control of infection Itraconazole: Start 200 mg 
bid, adjust with TDM 
A II No data to indicate which agent is 
preferable 
[364, 
745] 
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Voriconazole Start 150-200 
mg bid, adjust with TDM 
Voriconazole preferred for CNPA and 
patients with fungal balls to minimize risk 
of resistance 
[366, 
746, 
747] 
Posaconazole 
400 mg bid (oral suspension) 
300 mg qd (delayed release 
tablets) 
B II Higher rate of adverse events, if some 
adverse events with itraconazole and 
voriconazole 
[748] 
SoR, Strength of recommendation; QoE, Quality of evidence; CPA, chronic pulmonary aspergillosis; ABPA, allergic bronchopulmonary aspergillosis; SAIA, 794 
subacute invasive aspergillosis; CNPA, chronic necrotising pulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; qd, once daily; bid, twice 795 
daily; TDM, therapeutic drug monitoring 796 
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Figure 1. Management during neutropenia 798 
 799 
 
MiŶiŵuŵ diagŶostiĐ proĐedures: CT aŶd ŵiĐroďiologiĐal ǁork-up ;ĐǇtologǇ, Đulture & ďioŵarkersͿ 
CT Ŷegative / ďioŵarker Ŷegative: 
If prophǇlaǆis: CoŶtiŶue prophǇlaǆis, ĐoŶsider TDM, aŶd 
aĐtiǀelǇ eǆĐlude alterŶatiǀe foĐi ;e.g. siŶusitisͿ 
If Ŷo prophǇlaǆis: No aŶtifuŶgals aŶd aĐtiǀelǇ eǆĐlude 
alterŶatiǀe foĐi ;e.g. siŶusitisͿ 
 
CT positive / ďioŵarker Ŷegative: 
If prophǇlaǆis: DisĐoŶtiŶue prophǇlaǆis or ĐoŶsider TDM. 
Treat as reĐoŵŵeŶded for targeted treatŵeŶt, ďut ĐhaŶge 
aŶtifuŶgal Đlass 
If Ŷo prophǇlaǆis: “tart aŶtifuŶgal therapǇ for feǀer-driǀeŶ 
strategǇ 
DefiŶitioŶ of patieŶt populatioŶs: 
GM ;aŶd PC‘Ϳ ŵoŶitoriŶg O‘ ŵould-aĐtiǀe prophǇlaǆis 
“Ǉŵptoŵs ;e.g. persisteŶt feǀerͿ Positiǀe GM or PC‘ 
CT Ŷegative / ďioŵarker positive: 
AĐtiǀelǇ eǆĐlude alterŶatiǀe foĐi ;e.g. siŶusitisͿ. Treat as 
reĐoŵŵeŶded for targeted treatŵeŶt, ďut ĐhaŶge aŶtifuŶgal 
Đlass if prophǇlaǆis ǁas giǀeŶ 
CT positive / ďioŵarker positive: 
Treat as reĐoŵŵeŶded for targeted treatŵeŶt, ďut ĐhaŶge 
aŶtifuŶgal Đlass if prophǇlaǆis ǁas giǀeŶ 
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